WO2022150759A1 - Antibodies targeted to cd147 - Google Patents
Antibodies targeted to cd147 Download PDFInfo
- Publication number
- WO2022150759A1 WO2022150759A1 PCT/US2022/011969 US2022011969W WO2022150759A1 WO 2022150759 A1 WO2022150759 A1 WO 2022150759A1 US 2022011969 W US2022011969 W US 2022011969W WO 2022150759 A1 WO2022150759 A1 WO 2022150759A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- cancer
- cell
- virus
- hours
- Prior art date
Links
- 102100032412 Basigin Human genes 0.000 claims abstract description 91
- 101000798441 Homo sapiens Basigin Proteins 0.000 claims abstract description 89
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 66
- 201000011510 cancer Diseases 0.000 claims abstract description 56
- 230000003612 virological effect Effects 0.000 claims abstract description 38
- 230000009545 invasion Effects 0.000 claims abstract description 36
- 238000000034 method Methods 0.000 claims abstract description 35
- 230000004054 inflammatory process Effects 0.000 claims abstract description 21
- 206010061218 Inflammation Diseases 0.000 claims abstract description 20
- 210000004027 cell Anatomy 0.000 claims description 230
- 238000012986 modification Methods 0.000 claims description 114
- 230000004048 modification Effects 0.000 claims description 114
- 230000007423 decrease Effects 0.000 claims description 74
- 239000008194 pharmaceutical composition Substances 0.000 claims description 66
- 241000700605 Viruses Species 0.000 claims description 52
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 45
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims description 42
- 239000000611 antibody drug conjugate Substances 0.000 claims description 42
- 229940049595 antibody-drug conjugate Drugs 0.000 claims description 42
- 239000012634 fragment Substances 0.000 claims description 42
- 239000003814 drug Substances 0.000 claims description 39
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 36
- 238000011282 treatment Methods 0.000 claims description 32
- 229940079593 drug Drugs 0.000 claims description 26
- 210000004881 tumor cell Anatomy 0.000 claims description 25
- 241000711573 Coronaviridae Species 0.000 claims description 23
- 208000009182 Parasitemia Diseases 0.000 claims description 23
- 208000030852 Parasitic disease Diseases 0.000 claims description 23
- 208000023275 Autoimmune disease Diseases 0.000 claims description 22
- 238000003556 assay Methods 0.000 claims description 21
- 208000027866 inflammatory disease Diseases 0.000 claims description 20
- 230000003993 interaction Effects 0.000 claims description 20
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims description 19
- 230000002757 inflammatory effect Effects 0.000 claims description 19
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 18
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 18
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 18
- 241000711804 Infectious hematopoietic necrosis virus Species 0.000 claims description 18
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 18
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 18
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 18
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 18
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 18
- 230000033115 angiogenesis Effects 0.000 claims description 18
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 18
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 17
- 241000223960 Plasmodium falciparum Species 0.000 claims description 17
- 150000001413 amino acids Chemical class 0.000 claims description 17
- 210000000601 blood cell Anatomy 0.000 claims description 17
- 241001678559 COVID-19 virus Species 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 206010027476 Metastases Diseases 0.000 claims description 14
- 206010060862 Prostate cancer Diseases 0.000 claims description 14
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 14
- 239000002246 antineoplastic agent Substances 0.000 claims description 14
- 230000009401 metastasis Effects 0.000 claims description 14
- 229940041181 antineoplastic drug Drugs 0.000 claims description 13
- 239000003443 antiviral agent Substances 0.000 claims description 13
- 239000011159 matrix material Substances 0.000 claims description 13
- 239000000427 antigen Substances 0.000 claims description 12
- 108091007433 antigens Proteins 0.000 claims description 12
- 102000036639 antigens Human genes 0.000 claims description 12
- 230000004709 cell invasion Effects 0.000 claims description 12
- 230000003405 preventing effect Effects 0.000 claims description 12
- 230000015556 catabolic process Effects 0.000 claims description 11
- 238000006731 degradation reaction Methods 0.000 claims description 11
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 11
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 10
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 10
- 210000002865 immune cell Anatomy 0.000 claims description 10
- 201000005202 lung cancer Diseases 0.000 claims description 10
- 208000020816 lung neoplasm Diseases 0.000 claims description 10
- 208000026872 Addison Disease Diseases 0.000 claims description 9
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 9
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 9
- 206010005003 Bladder cancer Diseases 0.000 claims description 9
- 206010005949 Bone cancer Diseases 0.000 claims description 9
- 208000018084 Bone neoplasm Diseases 0.000 claims description 9
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 9
- 206010006187 Breast cancer Diseases 0.000 claims description 9
- 208000026310 Breast neoplasm Diseases 0.000 claims description 9
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 9
- 208000015943 Coeliac disease Diseases 0.000 claims description 9
- 206010009944 Colon cancer Diseases 0.000 claims description 9
- 208000011231 Crohn disease Diseases 0.000 claims description 9
- 241000709661 Enterovirus Species 0.000 claims description 9
- 241000991587 Enterovirus C Species 0.000 claims description 9
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 9
- 208000003807 Graves Disease Diseases 0.000 claims description 9
- 208000015023 Graves' disease Diseases 0.000 claims description 9
- 208000001204 Hashimoto Disease Diseases 0.000 claims description 9
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 9
- 241000711549 Hepacivirus C Species 0.000 claims description 9
- 241000700721 Hepatitis B virus Species 0.000 claims description 9
- 241000709721 Hepatovirus A Species 0.000 claims description 9
- 208000007514 Herpes zoster Diseases 0.000 claims description 9
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 9
- 206010061598 Immunodeficiency Diseases 0.000 claims description 9
- 208000029462 Immunodeficiency disease Diseases 0.000 claims description 9
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 9
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 9
- 201000005505 Measles Diseases 0.000 claims description 9
- 208000025370 Middle East respiratory syndrome Diseases 0.000 claims description 9
- 241000711386 Mumps virus Species 0.000 claims description 9
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 9
- 206010033128 Ovarian cancer Diseases 0.000 claims description 9
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 9
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 9
- 241000224016 Plasmodium Species 0.000 claims description 9
- 241000125945 Protoparvovirus Species 0.000 claims description 9
- 206010038389 Renal cancer Diseases 0.000 claims description 9
- 241001137860 Rotavirus A Species 0.000 claims description 9
- 241001137861 Rotavirus B Species 0.000 claims description 9
- 241001506005 Rotavirus C Species 0.000 claims description 9
- 241000710799 Rubella virus Species 0.000 claims description 9
- 241000700584 Simplexvirus Species 0.000 claims description 9
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 9
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 9
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 9
- 206010057644 Testis cancer Diseases 0.000 claims description 9
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 9
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 9
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 9
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 9
- 201000010881 cervical cancer Diseases 0.000 claims description 9
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 9
- 208000029742 colonic neoplasm Diseases 0.000 claims description 9
- 208000035475 disorder Diseases 0.000 claims description 9
- 241001493065 dsRNA viruses Species 0.000 claims description 9
- 210000002919 epithelial cell Anatomy 0.000 claims description 9
- 210000003743 erythrocyte Anatomy 0.000 claims description 9
- 201000004101 esophageal cancer Diseases 0.000 claims description 9
- 206010017758 gastric cancer Diseases 0.000 claims description 9
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 9
- 208000006454 hepatitis Diseases 0.000 claims description 9
- 231100000283 hepatitis Toxicity 0.000 claims description 9
- 230000007813 immunodeficiency Effects 0.000 claims description 9
- 238000009169 immunotherapy Methods 0.000 claims description 9
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 9
- 201000010982 kidney cancer Diseases 0.000 claims description 9
- 208000032839 leukemia Diseases 0.000 claims description 9
- 201000007270 liver cancer Diseases 0.000 claims description 9
- 208000014018 liver neoplasm Diseases 0.000 claims description 9
- 230000001926 lymphatic effect Effects 0.000 claims description 9
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 9
- 208000026037 malignant tumor of neck Diseases 0.000 claims description 9
- 201000006417 multiple sclerosis Diseases 0.000 claims description 9
- 206010028417 myasthenia gravis Diseases 0.000 claims description 9
- 201000002528 pancreatic cancer Diseases 0.000 claims description 9
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 9
- 201000000849 skin cancer Diseases 0.000 claims description 9
- 201000011549 stomach cancer Diseases 0.000 claims description 9
- 201000003120 testicular cancer Diseases 0.000 claims description 9
- 241000712461 unidentified influenza virus Species 0.000 claims description 9
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 9
- 206010046766 uterine cancer Diseases 0.000 claims description 9
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims description 8
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims description 8
- 229940096437 Protein S Drugs 0.000 claims description 8
- 101710198474 Spike protein Proteins 0.000 claims description 8
- 230000003247 decreasing effect Effects 0.000 claims description 8
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 8
- 230000002829 reductive effect Effects 0.000 claims description 8
- 239000003430 antimalarial agent Substances 0.000 claims description 6
- 210000004698 lymphocyte Anatomy 0.000 claims description 6
- 201000004792 malaria Diseases 0.000 claims description 6
- 241000223821 Plasmodium malariae Species 0.000 claims description 5
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 5
- 210000002889 endothelial cell Anatomy 0.000 claims description 5
- 230000002489 hematologic effect Effects 0.000 claims description 5
- 210000002569 neuron Anatomy 0.000 claims description 5
- 229940118768 plasmodium malariae Drugs 0.000 claims description 5
- 230000028327 secretion Effects 0.000 claims description 5
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 4
- 241000223801 Plasmodium knowlesi Species 0.000 claims description 4
- 241001505293 Plasmodium ovale Species 0.000 claims description 4
- 241000223810 Plasmodium vivax Species 0.000 claims description 4
- 229940124599 anti-inflammatory drug Drugs 0.000 claims description 4
- 230000004663 cell proliferation Effects 0.000 claims description 4
- 238000002659 cell therapy Methods 0.000 claims description 4
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 4
- 244000309459 oncolytic virus Species 0.000 claims description 4
- 229960005486 vaccine Drugs 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 210000000822 natural killer cell Anatomy 0.000 claims description 3
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 claims 2
- 230000009385 viral infection Effects 0.000 abstract description 13
- 208000036142 Viral infection Diseases 0.000 abstract description 12
- 244000045947 parasite Species 0.000 abstract description 7
- 230000003833 cell viability Effects 0.000 abstract description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 76
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 76
- 108090000765 processed proteins & peptides Proteins 0.000 description 60
- 102000004196 processed proteins & peptides Human genes 0.000 description 56
- 229920001184 polypeptide Polymers 0.000 description 52
- 102100024952 Protein CBFA2T1 Human genes 0.000 description 50
- 230000037396 body weight Effects 0.000 description 32
- 208000025721 COVID-19 Diseases 0.000 description 31
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 26
- 208000024891 symptom Diseases 0.000 description 23
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 19
- 230000000694 effects Effects 0.000 description 17
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 15
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- 241000725303 Human immunodeficiency virus Species 0.000 description 14
- 238000010186 staining Methods 0.000 description 14
- 235000002639 sodium chloride Nutrition 0.000 description 13
- 229940124597 therapeutic agent Drugs 0.000 description 13
- -1 0X40 Proteins 0.000 description 12
- 238000002560 therapeutic procedure Methods 0.000 description 12
- 230000035899 viability Effects 0.000 description 12
- 102000035195 Peptidases Human genes 0.000 description 11
- 108091005804 Peptidases Proteins 0.000 description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 229910052760 oxygen Inorganic materials 0.000 description 11
- 239000001301 oxygen Substances 0.000 description 11
- 230000004927 fusion Effects 0.000 description 10
- 235000019833 protease Nutrition 0.000 description 10
- 241001529936 Murinae Species 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 235000015067 sauces Nutrition 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 108010029485 Protein Isoforms Proteins 0.000 description 7
- 102000001708 Protein Isoforms Human genes 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 6
- 108010067390 Viral Proteins Proteins 0.000 description 6
- 238000004220 aggregation Methods 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- 238000013467 fragmentation Methods 0.000 description 6
- 238000006062 fragmentation reaction Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 230000010304 tumor cell viability Effects 0.000 description 6
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 5
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 5
- 230000002776 aggregation Effects 0.000 description 5
- 230000001363 autoimmune Effects 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 5
- 230000001934 delay Effects 0.000 description 5
- 201000001441 melanoma Diseases 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 201000004193 respiratory failure Diseases 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 4
- 108010064528 Basigin Proteins 0.000 description 4
- 208000000059 Dyspnea Diseases 0.000 description 4
- 206010013975 Dyspnoeas Diseases 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 239000006180 TBST buffer Substances 0.000 description 4
- 150000001540 azides Chemical class 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229960003677 chloroquine Drugs 0.000 description 4
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 230000004068 intracellular signaling Effects 0.000 description 4
- 231100000516 lung damage Toxicity 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000036387 respiratory rate Effects 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- 230000003442 weekly effect Effects 0.000 description 4
- 108010087819 Fc receptors Proteins 0.000 description 3
- 102000009109 Fc receptors Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 description 3
- 102100032818 Integrin alpha-4 Human genes 0.000 description 3
- 102100032816 Integrin alpha-6 Human genes 0.000 description 3
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 102100029215 Signaling lymphocytic activation molecule Human genes 0.000 description 3
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000005399 mechanical ventilation Methods 0.000 description 3
- 210000005087 mononuclear cell Anatomy 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 208000013220 shortness of breath Diseases 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 2
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 2
- 102000015279 Basigin Human genes 0.000 description 2
- 102100024263 CD160 antigen Human genes 0.000 description 2
- 208000001528 Coronaviridae Infections Diseases 0.000 description 2
- 208000028399 Critical Illness Diseases 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 description 2
- 101001078158 Homo sapiens Integrin alpha-1 Proteins 0.000 description 2
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 description 2
- 101001046687 Homo sapiens Integrin alpha-E Proteins 0.000 description 2
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 101000633786 Homo sapiens SLAM family member 6 Proteins 0.000 description 2
- 101000633780 Homo sapiens Signaling lymphocytic activation molecule Proteins 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 2
- 102100025323 Integrin alpha-1 Human genes 0.000 description 2
- 102100022341 Integrin alpha-E Human genes 0.000 description 2
- 102100025304 Integrin beta-1 Human genes 0.000 description 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000712079 Measles morbillivirus Species 0.000 description 2
- 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 206010038687 Respiratory distress Diseases 0.000 description 2
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 2
- 102100029197 SLAM family member 6 Human genes 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 2
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 229940052143 bamlanivimab Drugs 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000000139 costimulatory effect Effects 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 229940051243 etesevimab Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000002618 extracorporeal membrane oxygenation Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 208000037819 metastatic cancer Diseases 0.000 description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- RWWYLEGWBNMMLJ-MEUHYHILSA-N remdesivir Drugs C([C@@H]1[C@H]([C@@H](O)[C@@](C#N)(O1)C=1N2N=CN=C(N)C2=CC=1)O)OP(=O)(N[C@@H](C)C(=O)OCC(CC)CC)OC1=CC=CC=C1 RWWYLEGWBNMMLJ-MEUHYHILSA-N 0.000 description 2
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 230000000153 supplemental effect Effects 0.000 description 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 2
- 238000002627 tracheal intubation Methods 0.000 description 2
- 210000005239 tubule Anatomy 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- JSHOVKSMJRQOGY-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(pyridin-2-yldisulfanyl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCSSC1=CC=CC=N1 JSHOVKSMJRQOGY-UHFFFAOYSA-N 0.000 description 1
- GTBCXYYVWHFQRS-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(pyridin-2-yldisulfanyl)pentanoate Chemical compound C=1C=CC=NC=1SSC(C)CCC(=O)ON1C(=O)CCC1=O GTBCXYYVWHFQRS-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 244000303258 Annona diversifolia Species 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 1
- 108010056102 CD100 antigen Proteins 0.000 description 1
- 108010017009 CD11b Antigen Proteins 0.000 description 1
- 102100038077 CD226 antigen Human genes 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 108010062802 CD66 antigens Proteins 0.000 description 1
- 102100027217 CD82 antigen Human genes 0.000 description 1
- 101710139831 CD82 antigen Proteins 0.000 description 1
- 102100035793 CD83 antigen Human genes 0.000 description 1
- 101100326202 Caenorhabditis elegans him-6 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
- 208000032862 Clinical Deterioration Diseases 0.000 description 1
- 241000494545 Cordyline virus 2 Species 0.000 description 1
- 108010061994 Coronavirus Spike Glycoprotein Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 108010072220 Cyclophilin A Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 241001044073 Cypa Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 102100036254 E3 SUMO-protein ligase PIAS2 Human genes 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 101000585551 Equus caballus Pregnancy-associated glycoprotein Proteins 0.000 description 1
- XZWYTXMRWQJBGX-VXBMVYAYSA-N FLAG peptide Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 XZWYTXMRWQJBGX-VXBMVYAYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 102100022086 GRB2-related adapter protein 2 Human genes 0.000 description 1
- 101000798427 Gallus gallus Basigin Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000013875 Heart injury Diseases 0.000 description 1
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 description 1
- 102100022132 High affinity immunoglobulin epsilon receptor subunit gamma Human genes 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
- 101000900690 Homo sapiens GRB2-related adapter protein 2 Proteins 0.000 description 1
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 description 1
- 101000824104 Homo sapiens High affinity immunoglobulin epsilon receptor subunit gamma Proteins 0.000 description 1
- 101001035237 Homo sapiens Integrin alpha-D Proteins 0.000 description 1
- 101001046683 Homo sapiens Integrin alpha-L Proteins 0.000 description 1
- 101001046668 Homo sapiens Integrin alpha-X Proteins 0.000 description 1
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
- 101001015037 Homo sapiens Integrin beta-7 Proteins 0.000 description 1
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 description 1
- 101000971538 Homo sapiens Killer cell lectin-like receptor subfamily F member 1 Proteins 0.000 description 1
- 101001047640 Homo sapiens Linker for activation of T-cells family member 1 Proteins 0.000 description 1
- 101001090688 Homo sapiens Lymphocyte cytosolic protein 2 Proteins 0.000 description 1
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 description 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 1
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 description 1
- 101000873418 Homo sapiens P-selectin glycoprotein ligand 1 Proteins 0.000 description 1
- 101001124867 Homo sapiens Peroxiredoxin-1 Proteins 0.000 description 1
- 101000692259 Homo sapiens Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Proteins 0.000 description 1
- 101000702132 Homo sapiens Protein spinster homolog 1 Proteins 0.000 description 1
- 101000633778 Homo sapiens SLAM family member 5 Proteins 0.000 description 1
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 description 1
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 description 1
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 description 1
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 description 1
- 101000795169 Homo sapiens Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 description 1
- 101000648507 Homo sapiens Tumor necrosis factor receptor superfamily member 14 Proteins 0.000 description 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 1
- 101000679857 Homo sapiens Tumor necrosis factor receptor superfamily member 3 Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100039904 Integrin alpha-D Human genes 0.000 description 1
- 102100022339 Integrin alpha-L Human genes 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 102100022297 Integrin alpha-X Human genes 0.000 description 1
- 108010041100 Integrin alpha6 Proteins 0.000 description 1
- 108010030465 Integrin alpha6beta1 Proteins 0.000 description 1
- 102100025390 Integrin beta-2 Human genes 0.000 description 1
- 102100033016 Integrin beta-7 Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 description 1
- 102100021458 Killer cell lectin-like receptor subfamily F member 1 Human genes 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 1
- 102100024032 Linker for activation of T-cells family member 1 Human genes 0.000 description 1
- 102100034709 Lymphocyte cytosolic protein 2 Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 1
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 description 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 1
- 102400001263 NT-proBNP Human genes 0.000 description 1
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 description 1
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 description 1
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 description 1
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 description 1
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 description 1
- 101710141230 Natural killer cell receptor 2B4 Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 102100034925 P-selectin glycoprotein ligand 1 Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102100034539 Peptidyl-prolyl cis-trans isomerase A Human genes 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 102100026066 Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Human genes 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 1
- 102000014128 RANK Ligand Human genes 0.000 description 1
- 108010025832 RANK Ligand Proteins 0.000 description 1
- 229940125677 REGEN-COV Drugs 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 102100029216 SLAM family member 5 Human genes 0.000 description 1
- 102100029198 SLAM family member 7 Human genes 0.000 description 1
- 102100027744 Semaphorin-4D Human genes 0.000 description 1
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 description 1
- 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102100027208 T-cell antigen CD7 Human genes 0.000 description 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 102100035268 T-cell surface protein tactile Human genes 0.000 description 1
- 101150109894 TGFA gene Proteins 0.000 description 1
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 description 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 1
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 1
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 1
- 102100022156 Tumor necrosis factor receptor superfamily member 3 Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 101001038499 Yarrowia lipolytica (strain CLIB 122 / E 150) Lysine acetyltransferase Proteins 0.000 description 1
- JNWFIPVDEINBAI-UHFFFAOYSA-N [5-hydroxy-4-[4-(1-methylindol-5-yl)-5-oxo-1H-1,2,4-triazol-3-yl]-2-propan-2-ylphenyl] dihydrogen phosphate Chemical compound C1=C(OP(O)(O)=O)C(C(C)C)=CC(C=2N(C(=O)NN=2)C=2C=C3C=CN(C)C3=CC=2)=C1O JNWFIPVDEINBAI-UHFFFAOYSA-N 0.000 description 1
- 229950009821 acalabrutinib Drugs 0.000 description 1
- WDENQIQQYWYTPO-IBGZPJMESA-N acalabrutinib Chemical compound CC#CC(=O)N1CCC[C@H]1C1=NC(C=2C=CC(=CC=2)C(=O)NC=2N=CC=CC=2)=C2N1C=CN=C2N WDENQIQQYWYTPO-IBGZPJMESA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 229940127190 anti-B4 blocked ricin immunoconjugate Drugs 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229950000971 baricitinib Drugs 0.000 description 1
- XUZMWHLSFXCVMG-UHFFFAOYSA-N baricitinib Chemical compound C1N(S(=O)(=O)CC)CC1(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 XUZMWHLSFXCVMG-UHFFFAOYSA-N 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- 229940051183 casirivimab Drugs 0.000 description 1
- 230000005101 cell tropism Effects 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 229960003728 ciclesonide Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229960005338 clevudine Drugs 0.000 description 1
- GBBJCSTXCAQSSJ-XQXXSGGOSA-N clevudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1[C@H](F)[C@@H](O)[C@H](CO)O1 GBBJCSTXCAQSSJ-XQXXSGGOSA-N 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000000562 conjugate Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 229960003834 dapagliflozin Drugs 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 229960004120 defibrotide Drugs 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
- 229940099217 desferal Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- ZCGNOVWYSGBHAU-UHFFFAOYSA-N favipiravir Chemical compound NC(=O)C1=NC(F)=CNC1=O ZCGNOVWYSGBHAU-UHFFFAOYSA-N 0.000 description 1
- 229950008454 favipiravir Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960000578 gemtuzumab Drugs 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- 229940051184 imdevimab Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000012004 kinetic exclusion assay Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 238000002640 oxygen therapy Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000011809 primate model Methods 0.000 description 1
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 1
- 229960000215 ruxolitinib Drugs 0.000 description 1
- 229950006348 sarilumab Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000013125 spirometry Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960005187 telmisartan Drugs 0.000 description 1
- 229960003989 tocilizumab Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 229960004626 umifenovir Drugs 0.000 description 1
- KCFYEAOKVJSACF-UHFFFAOYSA-N umifenovir Chemical compound CN1C2=CC(Br)=C(O)C(CN(C)C)=C2C(C(=O)OCC)=C1CSC1=CC=CC=C1 KCFYEAOKVJSACF-UHFFFAOYSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 230000007502 viral entry Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- CD147 also known as Basigin, EMMPRIN, Neurothelin
- Basigin also known as Basigin, EMMPRIN, Neurothelin
- CD147 is a transmembrane glycoprotein that belongs to the immunoglobulin superfamily.
- CD147 is involved in tumor development, plasmodium invasion and virus infection.
- CD147 has been investigated as a potential therapeutic target for cancer and immunological disorders such as rheumatoid arthritis.
- the present disclosure provides novel antibodies, antibody fragments, or modifications thereof that bind to CD 147 expressed on cells to prevent viral infection, inhibit malaria infection, inhibit angiogenesis, and decrease cell viability.
- an anti-CD147 antibody comprising a binding domain that comprises at least one CDR comprising at least 70% identity to an amino acid sequence selected from SEQ ID NOs: 16-39.
- the anti-CD147 antibody comprises two CDRs, wherein each of the two CDRs independently comprise at least 70% identity to an amino acid sequence selected from SEQ ID NOs: 16-39.
- the anti-CD147 antibody comprises three CDRs, wherein each of the three CDRs independently comprise at least 70% identity to an amino acid sequence selected from SEQ ID NOs: 16-39.
- the anti-CD 147 antibody comprises an amino acid sequence with at least 70% identity to a sequence selected from SEQ ID NOs: 4-15.
- the anti-CD147 antibody comprises an amino acid sequence selected from SEQ ID NOs: 4-15.
- the antibody is a full-length antibody, a monospecific antibody, a bispecific antibody, a trispecific antibody, an antigen-binding region, heavy chain, light chain, VhH, Vh, a CDR, a variable domain, scFv, Fc, Fv, Fab, F(ab)2, IgG, reduced IgG (rlgG), monospecific Fab2, bispecific Fab2, trispecific Fab3, diabody, bispecific diabody, trispecific triabody, minibody, nanobody, IgNAR, V-NAR, HcIgG, or a combination thereof.
- the antibody is the VhH.
- a binding region of a Chimeric Antigen Receptor comprises at least one CDR comprising at least 70% identity to an amino acid sequence selected from SEQ ID NOs: 16-39.
- the CAR is expressed on an immune cell.
- the immune cell is a PBMC, a lymphocyte, a T cell, or aNK cell.
- the anti-CD 147 antibody binds to a CD147 or fragment thereof expressed on the surface of a cell.
- the cell is an epithelial cell, an endothelial cell, or neuronal cell.
- the anti-CD 147 antibody reduces or eliminates interaction between a virus and CD 147. In some embodiments, the interaction comprises binding of the CD147 by the virus. In some embodiments, the anti- CD147 antibody reduces or eliminates a viral spike protein from binding to CD147. In some embodiments, the anti-CD 147 antibody reduces or eliminates viral invasion of a cell. In some embodiments, the anti-CD 147 antibody reduces or eliminates viral invasion of a cell by at least about 1-fold as determined by a viral infectivity assay.
- the virus is selected from the group consisting of: measles, coronavirus, SARS, MERS, infectious hematopoietic necrosis virus (IHNV), parvovirus, Herpes Simplex Virus, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, mumps virus, rubella virus, HIV, Influenza virus, Rhinovirus, Rotavirus A, Rotavirus B, Rotavirus C, Respiratory Syncytial Virus (RSV), Varicella zoster, Poliovirus, immunodeficiency virus (e.g., HIV), enveloped virus, RNA virus, and hepatitis.
- the virus is the coronavirus.
- the coronavirus is SARS-CoV-2.
- the cell is a cancer cell.
- the cell is a tumor cell.
- the cancer cell is from a hematological cancer.
- the tumor cell is from a cancer selected from the group consisting of: breast cancer, lung cancer, prostate cancer, ovarian cancer, brain cancer, liver cancer, cervical cancer, colon cancer, renal cancer, skin cancer, head & neck cancer, bone cancer, esophageal cancer, bladder cancer, uterine cancer, lymphatic cancer, stomach cancer, pancreatic cancer, testicular cancer, leukemia, acute lymphocytic leukemia (ALL), acute myelogenous leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), and mantle cell lymphoma (MCL).
- ALL acute lymphocytic leukemia
- AML acute myelogenous leukemia
- CLL chronic lymphocytic leukemia
- CML chronic myelog
- the anti-CD 147 antibody reduces or eliminates tumor cell proliferation, metastasis, secretion of matrix metalloproteinases, degradation of a tumor matrix, tumor cell invasion, and/or angiogenesis. In some embodiments, the anti-CD147 antibody reduces or eliminates inflammation. In some embodiments, the anti-CD 147 antibody is effective in reducing or eliminating an inflammatory or autoimmune disorder.
- the inflammatory or autoimmune disease is selected from the group consisting of: rheumatoid arthritis, systemic lupus erythematosus (SLE), celiac disease, inflammatory bowel disease, Hashimoto’s disease, Addison’s disease, Grave’s disease, type I diabetes, autoimmune thrombocytopenic purpura (ATP), idiopathic pulmonary fibrosis, idiopathic thrombocytopenia purpura (ITP), Crohn's disease, multiple sclerosis, and myasthenia gravis.
- the anti-CD 147 antibody is humanized.
- the anti-CD 147 antibody binds to a cell thereby preventing, inhibiting, or decreasing invasion of a Plasmodium parasite into the cell. In some embodiments, the invasion of the Plasmodium parasite into the cell is by at least about 1-fold. In some embodiments, the cell is a red blood cell. In some embodiments, the Plasmodium parasite is selected from the group consisting of: Plasmodium falciparum, Plasmodium malariae, Plasmodium ovale, Plasmodium vivax, and Plasmodium knowlesi.
- the anti-CD 147 antibody is effective in decreasing parasitemia in blood cells. In some embodiments, the anti-CD147 antibody decreases parasitemia in blood cells within about 48 hours. In some embodiments, the anti-CD 147 antibody decreases parasitemia in blood cells within about 96 hours. In some embodiments, administration of the anti-CD 147 antibody prevents, ameliorates, or treats malaria in a subject. [0008] Provided herein is also a method of preventing, treating, or ameliorating a disorder associated with CD147 expression in a subject in need thereof comprising administering an anti-CD147 antibody.
- composition comprising an effective amount of an anti-CD 147 antibody.
- an anti-CD147 antibody that comprises a CDR1, a CDR2, and a CDR3 region, wherein the CDR1 region is an amino acid sequence selected from the group consisting of: SEQ ID NO: 12-SEQ ID NO: 15, wherein the CDR2 region is an amino acid sequence selected from the group consisting of: SEQ ID NO: 16-SEQ ID NO: 19, wherein the CDR3 region is an amino acid sequence selected from the group consisting of: SEQ ID NO: 20-SEQ ID NO: 23, and wherein the anti-CD 147 antibody comprises from 0 to 5 amino acid modifications in at least one of the CDR1, CDR, or CDR3 regions.
- the anti-CD 147 antibody comprises from 0-3 amino acid modifications.
- the CDR1 region corresponds to SEQ ID NO: 18 or 22, wherein the CDR2 region corresponds to SEQ ID NO: 26 or 30, and wherein the CDR3 region corresponds to SEQ ID NO: 34 or 38.
- the anti-CD147 antibody comprises SEQ ID NO: 12 or SEQ ID NO: 14. In some embodiments, the anti-CD 147 antibody is humanized.
- a method of treatment comprising administering an effective amount of a pharmaceutical composition comprising an anti-CD147 antibody, wherein the anti- CD 147 antibody comprises a CDR1, a CDR2, and a CDR3 region, wherein the CDR1 region is an amino acid sequence selected from the group consisting of: SEQ ID NO: 16-SEQ ID NO: 23, wherein the CDR2 region is an amino acid sequence selected from the group consisting of: SEQ ID NO: 24-SEQ ID NO: 31, wherein the CDR3 region is an amino acid sequence selected from the group consisting of: SEQ ID NO: 32-SEQ ID NO: 39, and wherein the anti-CD147 antibody comprises from 0 to 2 amino acid modifications in at least one of the CDR1, CDR, or CDR3 regions.
- the administering is effective in reducing or eliminating an inflammatory or autoimmune disease.
- the inflammatory or autoimmune disease is selected from the group consisting of: rheumatoid arthritis, systemic lupus erythematosus (SLE), celiac disease, inflammatory bowel disease, Hashimoto’s disease, Addison’s disease, Grave’s disease, type I diabetes, autoimmune thrombocytopenic purpura (ATP), idiopathic pulmonary fibrosis, idiopathic thrombocytopenia purpura (ITP), Crohn's disease, multiple sclerosis, and myasthenia gravis.
- the administering is effective in reducing or eliminating viral invasion of a cell by a virus.
- the virus is selected from the group consisting of: measles, coronavirus, SARS, MERS, infectious hematopoietic necrosis virus (IHNV), parvovirus, Herpes Simplex Virus, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, mumps virus, rubella virus, HIV, Influenza virus, Rhinovirus, Rotavirus A, Rotavirus B, Rotavirus C, Respiratory Syncytial Virus (RSV), Varicella zoster, Poliovirus, immunodeficiency virus (e.g., HIV), enveloped virus, RNA virus, and hepatitis.
- IHNV infectious hematopoietic necrosis virus
- RSV Respiratory Syncytial Virus
- the virus is the coronavirus.
- the coronavirus comprises SARS-CoV-2.
- the administering is effective in reducing or eliminating metastasis of a cancer.
- the cancer is selected from the group consisting of breast cancer, lung cancer, prostate cancer, ovarian cancer, brain cancer, liver cancer, cervical cancer, colon cancer, renal cancer, skin cancer, head & neck cancer, bone cancer, esophageal cancer, bladder cancer, uterine cancer, lymphatic cancer, stomach cancer, pancreatic cancer, testicular cancer, leukemia, acute lymphocytic leukemia (ALL), acute myelogenous leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), and mantle cell lymphoma (MCL).
- the administering is effective in reducing or eliminating invasion of Plasmodium into a cell.
- an antibody-drug conjugate that comprises an anti-CD147 antibody.
- the drug is selected from the group consisting of an anti cancer drug, an anti-malaria drug, an anti-viral drug, a toxin, and an anti-inflammatory drug.
- the drug comprises the anti-viral drug, wherein the anti-viral drug is an anti-SARS-CoV-2 drug.
- the drug comprises the anti-cancer drug, wherein the anti-cancer drug comprises an immunotherapy.
- the immunotherapy is selected from the group consisting of an antibody, checkpoint inhibitor, cell therapy, cytokine, oncolytic virus, and vaccine.
- the ADC comprises an antibody.
- the antibody comprises SEQ ID NO: 12 or SEQ ID NO: 14. [0014] In some embodiments, the present disclosure provides an anti-CD147 antibody, antibody fragment, or modification thereof that binds to a CD 147 polypeptide. In some embodiments, the present disclosure provides an anti-CD 147 antibody or fragment thereof comprising an amino acid sequence having at least one CDR comprised in any of SEQ ID NOs: 16-39. In some embodiments, the antibody comprises two to six CDRs comprised in any of SEQ ID NOs: 16-39. In some embodiments, the antibody comprises all the CDRs comprised in any one of SEQ ID NOs: 16-39. In some embodiments, the antibody comprises an amino acid sequence at least 70% identical to any of SEQ ID NOs: 16-39. In some embodiments, the antibody comprises an amino acid sequence of any of SEQ ID NOs: 16-39.
- the anti-CD147 antibody is a full-length antibody, a monospecific antibody, abispecific antibody, a trispecific antibody, an antigen-binding region, heavy chain, light chain, VhH, Vh, VI, a CDR, a variable domain, scFv, Fc, Fv, Fab, F(ab)2, reduced IgG (rlgG), monospecific Fab2, bispecific Fab2, trispecific Fab3, diabody, bispecific diabody, trispecific triabody, minibody, nanobody, IgNAR, V-NAR, HcIgG, or a combination thereof.
- the anti-CD 147 antibody is a VhH.
- the anti-CD147 antibody is comprised in a Chimeric Antigen Receptor (CAR).
- CAR Chimeric Antigen Receptor
- the CAR is expressed from an immune cell.
- the immune cell is a PBMC, a lymphocyte, a T cell, or a NK cell.
- the anti-CD147 antibody, antibody fragment, or modification binds to a CD 147 polypeptide or fragment thereof expressed on the surface of a cell.
- the cell is an epithelial, endothelial, or neuronal cell.
- the cell is a tumor cell.
- the tumor cell is from a solid tumor.
- the tumor cell is from a hematological cancer.
- the tumor cell is from a cancer consisting of breast cancer, lung cancer, prostate cancer, ovarian cancer, brain cancer, liver cancer, cervical cancer, colon cancer, renal cancer, skin cancer, head & neck cancer, bone cancer, esophageal cancer, bladder cancer, uterine cancer, lymphatic cancer, stomach cancer, pancreatic cancer, testicular cancer, leukemia, acute lymphocytic leukemia (ALL), acute myelogenous leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), and mantle cell lymphoma (MCL).
- ALL acute lymphocytic leukemia
- AML acute myelogenous leukemia
- CLL chronic lymphocytic leukemia
- CML chronic myelogenous leukemia
- MCL mantle cell lymphoma
- the anti-CD147 antibody, antibody fragment, or modification inhibits interaction of a virus and CD 147.
- the anti-CD 147 antibody prevents or
- the anti-CD147 antibody reduces or eliminates viral invasion of a cell. In some embodiments, the anti-CD147 antibody prevents or reduces viral infection.
- the virus is selected from the group consisting of measles, coronavirus, SARS, MERS, SARS-CoV-2, infectious hematopoietic necrosis virus (IHNV), parvovirus, Herpes Simplex Virus, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, mumps virus, rubella virus, HIV, Influenza virus, Rhinovirus, Rotavirus A, Rotavirus B, Rotavirus C, Respiratory Syncytial Virus (RSV), Varicella zoster, Poliovirus, immunodeficiency virus (e.g. HIV), enveloped virus, RNA virus, and hepatitis.
- the virus is a coronavirus.
- the coronavirus is SARS-CoV- 2
- the anti-CD147 antibody, antibody fragment, or modification thereof prevents or reduces tumor cell proliferation, metastasis, the secretion of matrix metalloproteinases, the degradation of the matrix, tumor cell invasion, and/or angiogenesis.
- the anti-CD 147 antibody, antibody fragment, or modification thereof prevents or reduces inflammation.
- the antibody treats or ameliorates an inflammatory or autoimmune disorder.
- the inflammatory or autoimmune disease is selected from rheumatoid arthritis, systemic lupus erythematosus (SLE), celiac disease, inflammatory bowel disease, Hashimoto’s disease, Addison’s disease, Grave’s disease, type I diabetes, autoimmune thrombocytopenic purpura (ATP), idiopathic pulmonary fibrosis, idiopathic thrombocytopenia purpura (ITP), Crohn's disease, multiple sclerosis, and myasthenia gravis.
- the present disclosure provides a method of preventing, treating, or ameliorating a disorder associated with CD 147 expression in a subject in need thereof comprising administering the anti-CD 147 antibody, antibody fragment, or modification thereof described herein.
- the present disclosure provides a pharmaceutical composition comprising the anti-CD 147 antibody, antibody fragment, or modification thereof described herein.
- the present disclosure provides a cell comprising a sequence encoding the anti-CD 147 antibody, antibody fragment, or modification thereof described herein.
- Figure 1 shows an ELISA demonstrating the binding of anti-CD147 antibodies of the disclosure to CD147-coated plates.
- Figure 2 shows that none of the tested antibodies bind to murine (mouse) mCD147.
- Figure 3 shows a comparison of the binding of the tested antibodies to human and murine CD147.
- Figure 4 shows a steady state model of Ibx-77 binding to CD147.
- Figure 5 shows a kinetic model of Ibx-77 binding to CD147.
- Figure 6 shows a Kd/Ka kinetic model of Ibx-77 binding to CD147.
- Figure 7 shows a steady state 1:1 fitting model of Ibx-77 binding to CD147.
- Figure 8 shows Ibx-77 staining ofHEK-293 cells.
- Figure 9 shows Ibx-77 staining of HCC-1954 cells.
- Figure 10 shows Ibx-77 staining of HeLa cells.
- Figures 11A-B show Ibx-11, Ibx-13, and Ibx-77 staining of HCC-1954 cells.
- Figures 12A-B show Ibx-11, Ibx-13, and Ibx-77 staining of HeLa cells.
- Figure 13 shows Ibx-11 staining of Jurkat cells.
- Figures 14A-B show Ibx-11 and Ibx-13 staining of Vero E6 cells.
- Figures 15A-B show sensograms of Ibx-75 (A) and Ibx-74 (B).
- FIG 16 shows that Ibx-11 and Ibx-13 antibody-drug conjugates (ADCs) effectively kill MiaPaCa-2 cancer cells.
- Figure 17 shows difference in the pattern of aggregation between Ibx-series treated cells and control cells.
- Figure 18 shows imaging analysis measuring pixel size: 50pg/ml - 25 pg/ml Ibx- series antibodies show larger pixel sizes for the particles (aggregates) at 24 hours.
- Figure 19 shows images from this Jurkat aggregation assay counted at 18 hours and 24 hours.
- Figure 20 shows that at 24 hours, there was a significant decrease in single cell counts for Ibx-77 treated cells.
- Figure 21 demonstrates cells treated with either Ibx-76 or Ibx-77 showed an inhibition of angiogenesis in a tube-forming assay.
- Figure 22 shows the percent parasitemia in vitro after administration of Ibx-13 (AB1), MIF-2-5 (AB2), or VhH-Fc (AB3) at 48 and 96 hours.
- Figure 23A-B show the percent parasitemia in vitro after administration of Ibx-13, MF22.3 (AB2) and h378GL (AB3) at 1 pg/mL, 10 pg/mL, and 100 pg/mL.
- Figure 23A shows percent parasitemia at 48 hours after administration;
- Figure 23B shows percent parasitemia after 96 hours.
- Figure 24 shows A375 malignant melanoma cell viability after treatment with varying concentrations of Ibx-11, Ibx-13, or control antibodies.
- Figure 25 shows a comparison of A375 malignant melanoma cell viability after treatment with 30 nM of Ibx-11, Ibx-13, or control antibodies.
- Figure 26 shows PC3 prostate cancer cell viability after treatment with varying concentrations of Ibx-11, Ibx-13, or control antibodies.
- Figure 27 shows a comparison of PC3 prostate cancer cell viability after treatment with 30 nM of Ibx-11, Ibx-13, or control antibodies.
- CD147 is a highly glycosylated transmembrane protein of the immunoglobulin super family that acts as the main upstream stimulator of matrix metalloproteinases (MMPs). Expression levels of CD147 and MMPs are often increased in inflammatory processes and tumors and are associated with cancer progression. Cancer stem cells characterized by high cell surface CD147 expression produce more hyaluronan, resulting in stabilization of lipid rafts, as well as enhanced MMP and ABC drug transporter expression, resistance, and survival. [0052] In some embodiments, anti-CD 147 antibodies or fragments, or modifications thereof described herein can be used to treat or prevent the growth of a cancer.
- MMPs matrix metalloproteinases
- the anti-CD 147 antibodies or fragments, or modifications thereof, and modified versions treat or prevent the growth of a hematologic cancer.
- the anti-CD 147 antibodies or fragments, or modifications thereof treat or prevent the growth of a solid cancer.
- the anti-CD147 antibodies or fragments, or modifications thereof treat or prevent the growth of a hematological cancer.
- the anti-CD 147 antibodies or fragments, or modifications thereof treat or prevent the growth of a metastatic cancer.
- the cancer includes, but is not limited to, breast cancer, lung cancer, prostate cancer, ovarian cancer, brain cancer, liver cancer, cervical cancer, colon cancer, renal cancer, skin cancer, head & neck cancer, bone cancer, esophageal cancer, bladder cancer, uterine cancer, lymphatic cancer, stomach cancer, pancreatic cancer, testicular cancer, leukemia, acute lymphocytic leukemia (ALL), acute myelogenous leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), and mantle cell lymphoma (MCL).
- ALL acute lymphocytic leukemia
- AML acute myelogenous leukemia
- CLL chronic lymphocytic leukemia
- CML chronic myelogenous leukemia
- MCL mantle cell lymphoma
- the anti-CD147 antibodies, fragments, or modifications thereof may be used to treat or reduce inflammation in a subject.
- the inflammation is associated with an autoimmune or inflammatory disorder.
- the autoimmune or inflammatory disorder includes, but is not limited to, rheumatoid arthritis, systemic lupus erythematosus (SLE), celiac disease, inflammatory bowel disease, Hashimoto’s disease, Addison’s disease, Grave’s disease, type I diabetes, autoimmune thrombocytopenic purpura (ATP), idiopathic pulmonary fibrosis, idiopathic thrombocytopenia purpura (ITP), Crohn's disease, multiple sclerosis, and myasthenia gravis.
- the anti-CD 147 antibodies, fragments, or modifications thereof may be used to treat or reduce viral infection and/or viral load in a subject.
- the anti- CD147 antibodies, fragments, or modifications thereof may be used to prevent, inhibit, or reduce viral invasion into a cell.
- CD147 is known to be important for viral invasion of cells.
- CD 147 is known to be a functional entry receptor for measles virus invasion of epithelial cells Watanabe 2010. Further, during HIV-1 infection, the CD147 molecule can promote infection of the host cell by the HIV-1 virus through interaction with the virus- associated CyPA (Chenglong 2020).
- the viral infection is caused by a virus including, but not limited to, measles, coronavirus, SARS, MERS, SARS-CoV-2, infectious hematopoietic necrosis virus (IHNV), parvovirus, Herpes Simplex Virus, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, mumps virus, rubella virus, HIV, Influenza virus, Rhinovirus, Rotavirus A, Rotavirus B, Rotavirus C, Respiratory Syncytial Virus (RSV), Varicella zoster, Poliovirus, immunodeficiency virus (e.g. HIV), enveloped virus, RNA virus, and hepatitis.
- a virus including, but not limited to, measles, coronavirus, SARS, MERS, SARS-CoV-2, infectious hematopoietic necrosis virus (IHNV), parvovirus, Herpes Simplex Virus, Hepatitis A virus, Hepatitis B virus
- the anti-CD147 antibodies, fragments, or modifications thereof may be used to treat or reduce the symptoms of malaria in a subject.
- the anti-CD 147 antibodies, fragments, or modifications thereof may be used to prevent, inhibit, or reduce invasion of one or more Plasmodium strains into a cell.
- the cell is a red blood cell.
- the Plasmodium strain is selected from Plasmodium falciparum, Plasmodium malariae, Plasmodium ovale, Plasmodium vivax, and Plasmodium knowlesi.
- the anti-CD147 antibodies, fragments, or modifications thereof prevent the invasion of Plasmodium falciparum into a cell.
- the anti-CD147 antibodies, fragments, or modifications thereof prevent the invasion of multiple Plasmodium strains into a cell.
- the Plasmodium is Plasmodium falciparum.
- the Plasmodium is Plasmodium malariae.
- the anti-CD 147 antibody or fragment or modification thereof decreases parasitemia. In some embodiments, the anti-CD 147 antibody or fragment or modification thereof decreases parasitemia in blood cells. In some embodiments, the anti- CD 147 antibody or fragment or modification thereof decreases parasitemia in blood cells within 10 minutes to 120 hours.
- the anti-CD147 antibody or fragment or modification thereof decreases parasitemia in blood cells within about 10 minutes, about 20 minutes, about 30 minutes, about 40 minutes, about 50 minutes, about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 12 hours, about 15 hours, about 20 hours, about 24 hours, about 25 hours, about 30 hours, about 35 hours, about 36 hours, about 40 hours, about 45 hours, about 48 hours, about 50 hours, about 55 hours, about 60 hours, about 65 hours, about 70 hours, about 75 hours, about 80 hours, about 85 hours, about 90 hours, about 95 hours, about 96 hours, about 100 hours, about 105 hours, about 110 hours, about 115 hours, or about 120 hours.
- the anti-CD 147 antibody or fragment or modification thereof decreases parasitemia in blood cells within about 48 hours. In some embodiments, the anti-CD147 antibody or fragment or modification thereof decreases parasitemia in blood cells within about 96 hours. In some embodiments, the blood cells are red blood cells.
- SARS-CoV-2 As of January 2022, SARS-CoV-2 has infected more than 293 million people (>55 million in the USA), has claimed over 5.4 million lives worldwide (> 821, 408 in the USA) and continues to spread at an alarming rate without any signs of slowing down.
- One of the factors that contributes to the high virulence and pathogenicity of SARS-CoV-2 is its ability to infect multiple tissues resulting in organ failure and death in severe cases. Similar to other enveloped viruses, SARS-CoV-2 utilizes host-cell receptors to invade host cells ultimately resulting in tissue necrosis, organ damage, and eventually death.
- CD 147 is one such host cell receptor that facilitates viral entry.
- Angiotensin-converting enzyme 2 (ACE2) is generally recognized as the primary receptor for SARS-CoV-2 infection but other molecules are being reported as significantly contributing to the cell tropism for this virus.
- CD 147 has recently garnered attention for its role in SARS-CoV-2 cell invasion via direct interaction with the Spike protein Recognition Binding Domain (RBD) of the virus, with potential benefits observed in an open label clinical trial that demonstrated early resolution of COVID-19 symptoms in patients who were treated with anti- CD 147 antibody.
- RBD Spike protein Recognition Binding Domain
- the present disclosure provides novel antibodies that bind to CD147 and their use in preventing or ameliorating a condition or disease.
- the CD147 is expressed on the surface of a cell.
- anti- CD147 antibodies of the disclosure can exert their effect directly or indirectly.
- an anti-CD147 antibody binds to CD147 thereby directly reducing or eliminating binding of the CD147 by anything else (e.g., a virus or cancer cell).
- an anti-CD 147 antibody can sterically hinder binding of a CD 147 receptor thereby indirectly exerting its effect.
- an anti-CD 147 can deliver a blocking agent when complexed as part of an antibody-drug conjugate thereby indirectly reducing or eliminating binding to a CD 147 receptor.
- Any of the anti-CD 147 antibodies can be fully human, humanized, murine, rat, rabbit, and any combination thereof.
- an anti-CD147 antibody is humanized.
- an anti-CD147 antibody is fully human.
- the anti-CD 147 antibody binds to a human CD 147 polypeptide, isoform, or fragment thereof.
- the human CD 147 is an isoform.
- the CD 147 isoform is basigin or basigin-2, which has two immunoglobulin domains.
- the CD 147 isoform is basigin- 1, which has three immunoglobulin domains.
- the human CD147 polypeptide or fragment thereof is a polypeptide comprising the amino acid sequence of SEQ ID NO: 1.
- the human CD 147 polypeptide or fragment thereof is a polypeptide comprising at least about 70% sequence identity to SEQ ID NO: 1.
- the human CD 147 polypeptide or fragment thereof is a polypeptide comprising at least about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 99.1%, about 99.2%, about 99.3%, about 99.4%, about 99.5%, about 99.6%, about 99.7%, about 99.8%, about or about 99.9% to SEQ ID NO: 1.
- the CD147 polypeptide, isoform, or fragment thereof is expressed on the surface of a cell. In some embodiments, the sequence of the portion of the CD147 polypeptide, isoform, or fragment thereof involved in binding is not altered. In some embodiments, the sequence of the portion of the CD 147 polypeptide, isoform, or fragment thereof involved in binding is altered.
- the human CD147 polypeptide or fragment is a truncation of the polypeptide comprising the amino acid sequence of SEQ ID NO: 1.
- the polypeptide is truncated at the N-terminus.
- the polypeptide is truncated at the C-terminus.
- the polypeptide is truncated at both the N- and C-termini.
- the polypeptide is truncated by up to about 20 amino acids compared to the polypeptide of SEQ ID NO: 1.
- the polypeptide is truncated by about 20, about 19, about 18, about 17, about 16, about 15, about 14, about 13, about 12, about 11, about 10, about 9, about 8, about 7, about 6, about 5, about 4, about 3, about 2, or about 1 amino acid compared to the polypeptide of SEQ ID NO: 1.
- the anti-CD 147 antibody binds to a rodent CD 147 polypeptide or fragment thereof.
- the rodent CD 147 polypeptide or fragment thereof is a rat CD147.
- the rodent CD147 polypeptide or fragment thereof is a murine CD147.
- the murine CD147 polypeptide is a polypeptide comprising the amino acid sequence of SEQ ID NO: 2.
- the human CD147 polypeptide is a polypeptide comprising at least about 70% sequence identity to SEQ ID NO: 2. In some embodiments, the human CD147 polypeptide is a polypeptide comprising at least about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 99.1%, about 99.2%, about 99.3%, about 99.4%, about 99.5%, about 99.6%, about 99.7%, about 99.8%, about or about 99.9% to SEQ ID NO: 2. In some embodiments, the sequence of the portion of the polypeptide involved in binding CD147 is not altered. In some embodiments,
- the murine CD 147 polypeptide or fragment is a truncation of the polypeptide comprising the amino acid sequence of SEQ ID NO: 2.
- the polypeptide is truncated at the N-terminus.
- the polypeptide is truncated at the C-terminus.
- the polypeptide is truncated at both the N- and C-termini.
- the polypeptide is truncated by up to about 20 amino acids compared to the polypeptide of SEQ ID NO: 2.
- the polypeptide is truncated by about 20, about 19, about 18, about 17, about 16, about 15, about 14, about 13, about 12, about 11, about 10, about 9, about 8, about 7, about 6, about 5, about 4, about 3, about 2, or about 1 amino acid compared to the polypeptide of SEQ ID NO: 2.
- the CD 147 is expressed on an endothelial cell, epithelial cell, neuronal cell, immunological cell, blood cell, fibroblast, T-cell, Peripheral Blood Mononuclear Cell (PBMC), monocyte cell, or mononuclear cell.
- PBMC Peripheral Blood Mononuclear Cell
- the CD147 is aberrantly expressed on the surface of a cell.
- the CD147 is over-expressed on the surface of a cell.
- the CD147 is expressed by a cell of a tumor stroma.
- the antibody that binds to a CD 147 polypeptide or fragment thereof is a full length antibody, a monospecific antibody, a bispecific antibody, a trispecific antibody, an antigen-binding region, heavy chain, light chain, VhH, Vh, VI, a CDR, a variable domain, scFv, Fc, Fv, Fab, F(ab)2, reduced IgG (rlgG), monospecific Fab2, bispecific Fab2, trispecific Fab3, diabody, bispecific diabody, trispecific triabody, minibody, nanobody, IgNAR, V-NAR, HcIgG, or a combination thereof.
- any of the described anti-CD147 antibodies may comprise one or more linkers, tags, or both linkers and tags.
- any of the anti-CD147 antibody fusion constructs may be connected by way of one or more linkers, see for example fusion constructs in Table 1.
- a linker is a cleavage linker.
- a linker is not cleavable.
- a linker of the disclosure may be protease sensitive, pH sensitive, and/or glutathione sensitive.
- a cleavable linker may be utilized to release a drug more effectively at a target site (e.g., at a tumor).
- Exemplary cleavable linkers include but are not limited to: hydrazone, SPDB, SPP, vc, va, and combinations thereof.
- Exemplary non- cleavable linkers comprise: mcc and me.
- flexible linkers may be utilized in fusion constructs, for example a (GGGGS)3 (SEQ ID NO: 40) linker.
- Another linker that may be utilized comprises the EPKIPQPQPKPQPQPQPQPQPKPQPEP (SEQ ID NO: 41) sequence.
- a tag may be utilized.
- An exemplary tag may comprise a flag tag such as DYKDDDDK (SEQ ID NO: 42).
- the antibody that binds to a CD 147 polypeptide or fragment thereof comprises a VhH antibody. In some embodiments, the antibody that binds to a CD 147 polypeptide or fragment thereof is a VhH antibody. In some embodiments, the VhH antibody is selected from any of SEQ ID NOs: 4-15. In some embodiments, the VhH antibody comprises at least about 70% sequence identity to the sequence of any of SEQ ID NOs: 4-15.
- the VhH antibody comprises at least about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 99.1%, about 99.2%, about 99.3%, about 99.4%, about 99.5%, about 99.6%, about 99.7%, about 99.8%, about or about 99.9% to the sequence of any of SEQ ID NOs: 4-15.
- the anti-CD147 antibody comprises one or more CDRs found in one or more of any of SEQ ID NOs: 4-15. In some embodiments, the anti-CD147 antibody comprises one CDR found in one or more of any of SEQ ID NOs: 4-15. In some embodiments, the anti-CD 147 antibody comprises two CDRs found in one or more of any of SEQ ID NOs: 4-15. In some embodiments, the anti-CD147 antibody comprises two CDRs found in different sequences of any of SEQ ID NOs: 4-15. In some embodiments, the anti- CD147 antibody comprises three CDRs found in one or more of any of SEQ ID NOs: 4-15. In some embodiments, the anti-CD 147 antibody comprises three CDRs found in one or more different sequences of any of SEQ ID NOs: 4-15.
- the anti-CD 147 antibody comprises a CDR at least 70% identical to that of one or more CDRs found in any of SEQ ID NOs: 16-39. In some embodiments, the anti-CD147 antibody comprises one CDR at least about 70% identical to that of one or more CDRs found in one or more of any of SEQ ID NOs: 16-39. In some embodiments, the anti-CD 147 antibody comprises two CDRs at least about 70% identical to one or more CDRs found in one or more of any of SEQ ID NOs: 16-39. In some embodiments, the anti-CD147 antibody comprises two CDRs at least about 70% identical to one or more CDRs found in different sequence of any of SEQ ID NOs: 16-39.
- the anti-CD 147 antibody comprises three CDRs at least about 70% identical to one or more CDRs found in one or more of any of SEQ ID NOs: 16-39. In some embodiments, the anti-CD147 antibody comprises three CDRs at least about 70% identical to one or more CDRs found in one or more different sequences of any of SEQ ID NOs: 16-39.
- the one or more CDRs are at least about 60%, about 65%, about 70%, about 75%, 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, about 99.1%, about 99.2%, about 99.3%, about 99.4%, about 99.5%, about 99.6%, about 99.7%, about 99.8%, about or about 99.9% to one or more CDRs found in one or more of any of SEQ ID NOs: 16-39.
- the anti-CD147 antibody comprises a CDR1 that comprises at least about 60% identity to a sequence selected from the group consisting of: SEQ ID NO: 16-23.
- the anti-CD147 antibody comprises a CDR2 that comprises at least about 60% identity to a sequence selected from the group consisting of: SEQ ID NO: 24- 31.
- the anti-CD147 antibody comprises a CDR3 that comprises at least about 60% identity to a sequence selected from the group consisting of: SEQ ID NO: 32-39.
- the anti-CD 147 antibody comprises CDR1, CDR2, and CDR3 comprising SEQ ID NO: 16, 24, and 32 respectively.
- the anti-CD147 antibody comprises CDR1, CDR2, and CDR3 comprising SEQ ID NO: 17, 25, and 33 respectively. In some embodiments, the anti-CD 147 antibody comprises CDR1, CDR2, and CDR3 comprising SEQ ID NO: 18, 26, and 34 respectively. In some embodiments, the anti- CD147 antibody comprises CDR1, CDR2, and CDR3 comprising SEQ ID NO: 19, 27, and 35 respectively. In some embodiments, the anti-CD 147 antibody comprises CDR1, CDR2, and CDR3 comprising SEQ ID NO: 20, 28, and 36 respectively. In some embodiments, the anti- CD147 antibody comprises CDR1, CDR2, and CDR3 comprising SEQ ID NO: 21, 29, and 37 respectively.
- the anti-CD 147 antibody comprises CDR1, CDR2, and CDR3 comprising SEQ ID NO: 22, 30, and 38 respectively. In some embodiments, the anti- CD147 antibody comprises CDR1, CDR2, and CDR3 comprising SEQ ID NO: 23, 31, and 39 respectively. In some embodiments, the anti-CD147 antibody comprises three CDR1, CDR2, and/or CDR3 sequences in tandem. In embodiments, an anti-CD 147 antibody comprises, a CDR1, CDR2, or CDR3 in duplicate or triplicate, such as in any of the fusion constructs described herein. In some embodiments, a fusion construct may comprise any one of the CDR sequences described herein in tandem with one or more linkers.
- an anti-CD147 antibody described herein can comprise a modification.
- a modification comprises an amino acid substitution, deletion, and/or insertion. With regard to the modification, this may include any modification such as amino acid substitution, deletion and/or insertion at any location of a sequence. Hence, the modification may include a modification in sequence and/or length.
- a sequence comprises a CDR region. A CDR may thus be modified to vary in length ranging from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, and up to about 35 amino acid residues.
- any region of a CDR may be modified to include residue substitutions, deletions, and/or insertions ranging in length as previously described.
- a modification can comprise from about 0-2 residue modifications.
- a modification can comprise from about 1- 3, 2-4, 0-4, or 1-5 residue modifications at any one of CDR1, CDR2, and/or CDR3.
- any one of SEQ ID NO: 16- SEQ ID NO: 39 may have one or more modifications described herein.
- the anti-CD147 antibody or fragment thereof is part of a chimeric antigen receptor (CAR).
- CAR is a recombinant receptor composed of an extracellular antigen binding domain, a transmembrane domain, and an intracellular signaling domain.
- the intracellular signaling domain may comprise signaling domains from an immune cell.
- the immune cell is a mononuclear cell.
- the mononuclear cell is a PBMC, PBL, lymphocyte, B cell, T cell, Natural Killer (NK) cell, monocyte, dendritic cell, eosinophil, neutrophil, basophil, or Antigen Presenting Cell (APC).
- PBMC PBMC
- PBL lymphocyte
- B cell B cell
- T cell T cell
- Natural Killer (NK) cell monocyte
- dendritic cell eosinophil
- neutrophil neutrophil
- basophil basophil
- APC Antigen Presenting Cell
- a binding region of a CAR can comprise a CDR sequence disclosed herein.
- the binding region is normally fused to a transmembrane region, for example from CD8, which is also fused to an intracellular signaling domain.
- Suitable intracellular signaling domains can comprise an intracellular signal region sequence of CD3 zeta (O ⁇ 3z), CD3 gamma, CD3 delta, CD3 epsilon, common FcR gamma (FCER1G), FcR beta (Fc Epsilon Rib), CD79a, CD79b, Fc gamma Rlla, DAP10 and DAP12 molecules, or a combination thereof.
- the intracellular signal domain comprises a signaling domain of a O ⁇ 3z molecule.
- the intracellular signal domain also comprises a co-stimulatory signal domain, which may be selected from the following co-stimulatory signal molecules: CD27, CD28, 4-1BB, 0X40, CD30, CD40, CD2, lymphocyte function-associated antigen-1 (LFA-1), LIGHT, NKG2C, B7-H3, PD-1, ICOS, CDS, ICAM-1, GITR, BAFFR, HVEM (LIGHTR), SLAMF7, CD7, NKp80 (KLRFl), CD160, CD19, CD4, CD8 alpha, CD8 beta, IL2R beta, IL2R gamma, IL7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CDlld, ITGAE, CD103, ITGAL, CDlla, L
- binding affinity generally refers to the strength of the sum total of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless indicated otherwise, as used herein, “binding affinity” refers to intrinsic binding affinity which reflects a 1 : 1 interaction between members of a binding pair (e.g., antibody and antigen).
- the affinity of a molecule X for its partner Y can generally be represented by the dissociation constant (KD). Affinity can be measured and/or expressed in a number of ways known in the art, including, but not limited to, equilibrium dissociation constant (KD), and equilibrium association constant (KA).
- the KD is calculated from the quotient of k 0ff /k 0n
- KA is calculated from the quotient of kon/koff refers to the association rate constant of, e.g., an antibody to an antigen
- koff refers to the dissociation of, e.g., an antibody to an antigen.
- the k on and k 0ff can be determined by techniques known to one of ordinary skill in the art, such as BIACORE® or KinExA.
- the antibody binds to CD147 with a KD of about 50 nM or lower.
- the antibody binds to CD 147 with a KD in a range of about 250 pM to about 1 pM.
- the antibody binds to CD147 with a KD in a range of about 100 pM to about 1 pM. In some embodiments, antibody binds to CD 147 with an IC50 of about 200 nM or lower. In some embodiments, the antibody binds to CD 147 with an IC50 of about 100 nM to about 1 nM. In some embodiments, antibody binds to CD 147 with an IC50 of about 10 nM to about 1 nM.
- the antibody or fragment thereof of the present disclosure binds to a CD 147 on the surface of a cell. In some embodiments, the antibody binds to CD 147 on the surface of a cancer cell. In some embodiments, the antibody binds to CD 147 on the surface of a cancer cell that has not yet become metastatic. In some embodiments, the antibody binds to CD 147 on the surface of a metastatic cancer cell.
- the antibody or fragment thereof of the present disclosure binds to CD 147 on the surface of a virally -infected cell. In some embodiments, the antibody binds to CD147 on the surface of a cell that has not been infected by a virus. In some embodiments, binding of the antibody to the CD 147 on the surface of the cell prevents viral infection. In some embodiments, the antibody interferes with the interaction of the virus and the CD147 on the surface of the cell. In some embodiments, the antibody interferes with the interaction of a spike protein and CD147. In some embodiments, the spike protein is a coronavirus spike protein. In some embodiments, the spike protein is a SARS-CoV2 spike protein. In some embodiments, the antibody interferes with the virus/CD147 interaction and inhibits viral invasion and/or dissemination among other cells.
- the antibody, antibody fragment, or modification thereof completely blocks the interaction of a viral protein and CD147. In some embodiments, the antibody, antibody fragment, or modification thereof decreases the interaction of a viral protein and CD 147 compared to an untreated cell. In some embodiments, the antibody, antibody fragment, or modification thereof decreases the interaction of a viral protein and CD 147 by about 99.9% to about 1% compared to an untreated cell.
- the antibody, antibody fragment, or modification thereof decreases the interaction of a viral protein and CD147 by about 99.9%, about 99.8%, about 99.7%, about 99.6%, about 99.5%, about 99.4%, about 99.3%, about 99.2%, about 99.1%, about 99%, about 98%, about 97%, about 96%, about 95%, about 94%, about 93%, about 92%, about 91%, about 90%, about 89%, about 88%, about 87%, about 86%, about 85%, about 84%, about 83%, about 82%, about 81%, about 80%, about 79%, about 78%, about 77%, about 76%, about 75%, about 74%, about 73%, about 72%, about 71%, about 70%, about 69%, about 68%, about 67%, about 66%, about 65%, about 64%, about 63%, about 62%, about 61%, about 60%, about 59%, about 58%, about 57%, about 56%, about 55%, about 54%, about 5
- the antibody, antibody fragment, or modification thereof decreases the interaction of a viral protein and CD 147 at about 10 minutes to about 1 day after administration compared to an untreated cell. In some embodiments, the antibody, antibody fragment, or modification thereof decreases the interaction of a viral protein and CD 147 at about 5 minutes, about 10 minutes, about 20 minutes, about 30 minutes, about 40 minutes, about 50 minutes, about 60 minutes, about 70 minutes, about 80 minutes, about 90 minutes, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, or about 24 hours after administration compared to an untreated cell.
- the antibody, antibody fragment, or modification thereof completely prevents viral invasion of a cell. In some embodiments, the antibody, antibody fragment, or modification thereof decreases viral invasion of a cell compared to an untreated cell. In some embodiments, the antibody, antibody fragment, or modification thereof decreases viral invasion of a cell by about 99.9% to about 1% compared to an untreated cell.
- the antibody, antibody fragment, or modification thereof decreases viral invasion of a cell by about 99.9%, about 99.8%, about 99.7%, about 99.6%, about 99.5%, about 99.4%, about 99.3%, about 99.2%, about 99.1%, about 99%, about 98%, about 97%, about 96%, about 95%, about 94%, about 93%, about 92%, about 91%, about 90%, about 89%, about 88%, about 87%, about 86%, about 85%, about 84%, about 83%, about 82%, about 81%, about 80%, about 79%, about 78%, about 77%, about 76%, about 75%, about 74%, about 73%, about 72%, about 71%, about 70%, about 69%, about 68%, about 67%, about 66%, about 65%, about 64%, about 63%, about 62%, about 61%, about 60%, about 59%, about 58%, about 57%, about 56%, about 55%, about 54%, about 53%, about 5
- the antibody decreases viral invasion of a cell at about 10 minutes to about 1 day after administration compared to an untreated cell. In some embodiments, the antibody decreases viral invasion of a cell at about 5 minutes, about 10 minutes, about 20 minutes, about 30 minutes, about 40 minutes, about 50minutes, about 60 minutes, about 70 minutes, about 80 minutes, about 90 minutes, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, or about 24 hours after administration compared to an untreated cell.
- the cell is an epithelial cell.
- the anti-CD 147 antibody reduces or eliminates viral invasion of a cell by at least about 1-fold, 50-fold, 100- fold, 150-fold, 200-fold, 250-fold, 300-fold, 350-fold, 400-fold, 450-fold, 500-fold, 550-fold, 600-fold, 650-fold, 700-fold, 750-fold, 800-fold, 850-fold, 900-fold, 950-fold, 1000-fold, 1050-fold, 1100-fold, 1150-fold, 1200-fold, 1250-fold, 1300-fold, 1350-fold, 1400-fold, 1450- fold, 1500-fold, 1550-fold, 1600-fold, 1650-fold, 1700-fold, 1750-fold, 1800-fold, 1850-fold, 1900-fold, 1950-fold, or up to about 2000-fold, as determined by a viral infectivity assay described herein.
- Viral invasion or infection can be determined using an in vitro assay.
- a viral load can be quantified by counting viral RNA genomes by qRT-PCR and measuring the number of infectious units in tissue culture.
- the second approach comprises incubating susceptible mammalian cells with dilutions of a subject’s sample to determine the amount of sample required to kill 50% of the cells. This value is used to back-calculate the infectious titer in the sample in units of “50% tissue culture infective dose” or TCID50 for example, by the Reed and Muench method.
- the antibody, antibody fragment, or modification thereof completely prevents viral dissemination among cells. In some embodiments, the antibody, antibody fragment, or modification thereof decreases viral dissemination among cells compared to that in an untreated subject or cell culture. In some embodiments, the antibody, antibody fragment, or modification thereof decreases viral dissemination among cells by about 99.9% to about 1% compared to that in an untreated subject or cell culture.
- the antibody, antibody fragment, or modification thereof decreases viral dissemination among cells by about 99.9%, about 99.8%, about 99.7%, about 99.6%, about 99.5%, about 99.4%, about 99.3%, about 99.2%, about 99.1%, about 99%, about 98%, about 97%, about 96%, about 95%, about 94%, about 93%, about 92%, about 91%, about 90%, about 89%, about 88%, about 87%, about 86%, about 85%, about 84%, about 83%, about 82%, about 81%, about 80%, about 79%, about 78%, about 77%, about 76%, about 75%, about 74%, about 73%, about 72%, about 71%, about 70%, about 69%, about 68%, about 67%, about 66%, about 65%, about 64%, about 63%, about 62%, about 61%, about 60%, about 59%, about 58%, about 57%, about 56%, about 55%, about 54%, about 53%, about 52%,
- the antibody, antibody fragment, or modification thereof decreases viral dissemination among cells at about 5 minutes, about 10 minutes, about 20 minutes, about 30 minutes, about 40 minutes, about 50 minutes, about 60 minutes, about 70 minutes, about 80 minutes, about 90 minutes, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about
- administration of an antibody, antibody fragment, or modification thereof of the present disclosure decreases inflammation in a subject. In some embodiments, administration of the antibody, antibody fragment, or modification thereof decreases inflammation compared to the levels of inflammation in a similar untreated subject or the same subject before administration of the antibody. In some embodiments, administration of the antibody, antibody fragment, or modification thereof decreases inflammation by about 99.9% to about 1% compared to the levels of inflammation in a similar untreated subject or the same subject before administration of the antibody.
- administration of the antibody, antibody fragment, or modification thereof decreases inflammation by about 99.9%, about 99.8%, about 99.7%, about 99.6%, about 99.5%, about 99.4%, about 99.3%, about 99.2%, about 99.1%, about 99%, about 98%, about 97%, about 96%, about 95%, about 94%, about 93%, about 92%, about 91%, about 90%, about 89%, about 88%, about 87%, about 86%, about 85%, about 84%, about 83%, about 82%, about 81%, about 80%, about 79%, about 78%, about 77%, about 76%, about 75%, about 74%, about 73%, about 72%, about 71%, about 70%, about 69%, about 68%, about 67%, about 66%, about 65%, about 64%, about 63%, about 62%, about 61%, about 60%, about 59%, about 58%, about 57%, about 56%, about 55%, about 54%, about 53%, about 52%, about
- administration of the antibody, antibody fragment, or modification thereof decreases inflammation at about 10 minutes to about 1 day after administration compared to the levels of inflammation in a similar untreated subject or the same subject before administration of the antibody. In some embodiments, administration of the antibody, antibody fragment, or modification thereof decreases inflammation at about 5 minutes, about 10 minutes, about 20 minutes, about 30 minutes, about 40 minutes, about 50 minutes, about 60 minutes, about 70 minutes, about 80 minutes, about 90 minutes, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, or about 24 hours after administration compared to the levels of inflammation in a similar untreated subject or the same subject before administration of the antibody.
- the inflammation results in inflammatory lung damage.
- the decrease in inflammatory lung damage may be measured by any means known in the art.
- inflammatory lung damage and/or the symptoms thereof may be measured by assessing changes in oxygen levels in the patient, exhaled nitric oxide, respiratory rate, or spirometry measurements.
- administration of an antibody, antibody fragment, or modification thereof of the present disclosure decreases proteinase activity in a subject.
- the proteinase is a metalloproteinase.
- administration of the antibody, antibody fragment, or modification thereof decreases proteinase activity compared to the levels in a similar untreated subject or the same subject before administration of the antibody.
- administration of the antibody, antibody fragment, or modification thereof decreases proteinase activity by about 99.9% to about 1% compared to the levels in a similar untreated subject or the same subject before administration of the antibody.
- administration of the antibody, antibody fragment, or modification thereof decreases proteinase activity by about 99.9%, about 99.8%, about 99.7%, about 99.6%, about 99.5%, about 99.4%, about 99.3%, about 99.2%, about 99.1%, about 99%, about 98%, about 97%, about 96%, about 95%, about 94%, about 93%, about 92%, about 91%, about 90%, about 89%, about 88%, about 87%, about 86%, about 85%, about 84%, about 83%, about 82%, about 81%, about 80%, about 79%, about 78%, about 77%, about 76%, about 75%, about 74%, about 73%, about 72%, about 71%, about 70%, about 69%, about 68%, about 67%, about 66%, about 65%, about 64%, about 63%, about 62%, about 61%, about 60%, about 59%, about 58%, about 57%, about 56%, about 55%, about 54%, about 53%, about
- administration of the antibody, antibody fragment, or modification thereof decreases proteinase activity at about 10 minutes to about 1 day after administration compared to the levels of a similar untreated subject or the same subject before administration of the antibody. In some embodiments, administration of the antibody, antibody fragment, or modification thereof decreases proteinase activity at about 5 minutes, about 10 minutes, about 20 minutes, about 30 minutes, about 40 minutes, about 50 minutes, about 60 minutes, about 70 minutes, about 80 minutes, about 90 minutes, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, or about 24 hours after administration compared to the levels of in a similar untreated subject or the same subject before administration of the antibody.
- the proteinase is produced and/or secreted by a cell expressing CD147. In some embodiments, the proteinase is produced and/or secreted by a cancer cell. In some embodiments, the proteinase is produced and/or secreted by a cancer cell expressing CD 147.
- administration of an antibody, antibody fragment, or modification thereof of the present disclosure decreases matrix degradation in a subject. In some embodiments, administration of the antibody, antibody fragment, or modification thereof decreases matrix degradation compared to the levels in a similar untreated subject or the same subject before administration of the antibody. In some embodiments, administration of the antibody, antibody fragment, or modification thereof decreases matrix degradation by about 99.9% to about 1% compared to the levels in a similar untreated subject or the same subject before administration of the antibody.
- administration of the antibody, antibody fragment, or modification thereof decreases matrix degradation by about 99.9%, about 99.8%, about 99.7%, about 99.6%, about 99.5%, about 99.4%, about 99.3%, about 99.2%, about 99.1%, about 99%, about 98%, about 97%, about 96%, about 95%, about 94%, about 93%, about 92%, about 91%, about 90%, about 89%, about 88%, about 87%, about 86%, about 85%, about 84%, about 83%, about 82%, about 81%, about 80%, about 79%, about 78%, about 77%, about 76%, about 75%, about 74%, about 73%, about 72%, about 71%, about 70%, about 69%, about 68%, about 67%, about 66%, about 65%, about 64%, about 63%, about 62%, about 61%, about 60%, about 59%, about 58%, about 57%, about 56%, about 55%, about 54%, about 53%, about 52%,
- administration of the antibody, antibody fragment, or modification thereof decreases matrix degradation at about 10 minutes to about 1 day after administration compared to the levels in a similar untreated subject or the same subject before administration of the antibody. In some embodiments, administration of the antibody, antibody fragment, or modification thereof decreases matrix degradation at about 5 minutes, about 10 minutes, about 20 minutes, about 30 minutes, about 40 minutes, about 50 minutes, about 60 minutes, about 70 minutes, about 80 minutes, about 90 minutes, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, or about 24 hours after administration compared to the levels in a similar untreated subject or the same subject before administration of the antibody.
- administration of an antibody, antibody fragment, or modification thereof of the present disclosure decreases cell invasion in a subject. In some embodiments, administration of the antibody, antibody fragment, or modification thereof decreases cell invasion compared to the levels in a similar untreated subject or the same subject before administration of the antibody. In some embodiments, administration of the antibody, antibody fragment, or modification thereof decreases cell invasion by about 99.9% to about 1% compared to the levels in a similar untreated subject or the same subject before administration of the antibody.
- administration of the antibody, antibody fragment, or modification thereof decreases cell invasion by about 99.9%, about 99.8%, about 99.7%, about 99.6%, about 99.5%, about 99.4%, about 99.3%, about 99.2%, about 99.1%, about 99%, about 98%, about 97%, about 96%, about 95%, about 94%, about 93%, about 92%, about 91%, about 90%, about 89%, about 88%, about 87%, about 86%, about 85%, about 84%, about 83%, about 82%, about 81%, about 80%, about 79%, about 78%, about 77%, about 76%, about 75%, about 74%, about 73%, about 72%, about 71%, about 70%, about 69%, about 68%, about 67%, about 66%, about 65%, about 64%, about 63%, about 62%, about 61%, about 60%, about 59%, about 58%, about 57%, about 56%, about 55%, about 54%, about 53%, about 52%,
- administration of the antibody, antibody fragment, or modification thereof decreases cell invasion at about 10 minutes to about 1 day after administration compared to the levels in a similar untreated subject or the same subject before administration of the antibody. In some embodiments, administration of the antibody, antibody fragment, or modification thereof decreases cell invasion at about 5 minutes, about 10 minutes, about 20 minutes, about 30 minutes, about 40 minutes, about 50 minutes, about 60 minutes, about 70 minutes, about 80 minutes, about 90 minutes, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, or about 24 hours after administration compared to the levels in a similar untreated subject or the same subject before administration of the antibody. In some embodiments, the cell is a tumor cell.
- administration of an antibody, antibody fragment, or modification thereof of the present disclosure decreases tumor cell metastasis in a subject. In some embodiments, administration of the antibody, antibody fragment, or modification thereof decreases tumor cell metastasis compared to the levels in a similar untreated subject or the same subject before administration of the antibody. In some embodiments, administration of the antibody, antibody fragment, or modification thereof decreases tumor cell metastasis by about 99.9% to about 1% compared to the levels in a similar untreated subject or the same subject before administration of the antibody.
- administration of the antibody, antibody fragment, or modification thereof decreases tumor cell metastasis by about 99.9%, about 99.8%, about 99.7%, about 99.6%, about 99.5%, about 99.4%, about 99.3%, about 99.2%, about 99.1%, about 99%, about 98%, about 97%, about 96%, about 95%, about 94%, about 93%, about 92%, about 91%, about 90%, about 89%, about 88%, about 87%, about 86%, about 85%, about 84%, about 83%, about 82%, about 81%, about 80%, about 79%, about 78%, about 77%, about 76%, about 75%, about 74%, about 73%, about 72%, about 71%, about 70%, about 69%, about 68%, about 67%, about 66%, about 65%, about 64%, about 63%, about 62%, about 61%, about 60%, about 59%, about 58%, about 57%, about 56%, about 55%, about 54%, about 53%,
- administration of the antibody, antibody fragment, or modification thereof decreases tumor cell metastasis at about 10 minutes to about 1 day after administration compared to the levels in a similar untreated subject or the same subject before administration of the antibody. In some embodiments, administration of the antibody, antibody fragment, or modification thereof decreases tumor cell metastasis at about 5 minutes, about 10 minutes, about 20 minutes, about 30 minutes, about 40 minutes, about 50 minutes, about 60 minutes, about 70 minutes, about 80 minutes, about 90 minutes, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, or about 24 hours after administration compared to the levels in a similar untreated subject or the same subject before administration of the antibody.
- administration of an antibody, antibody fragment, or modification thereof of the present disclosure decreases tumor cell viability in a subject. In some embodiments, administration of the antibody, antibody fragment, or modification thereof decreases tumor cell viability compared to the levels in a similar untreated subject or the same subject before administration of the antibody. In some embodiments, administration of the antibody, antibody fragment, or modification thereof decreases tumor cell viability by about 99.9% to about 1% compared to the levels in a similar untreated subject or the same subject before administration of the antibody.
- administration of the antibody, antibody fragment, or modification thereof decreases tumor cell viability by about 99.9%, about 99.8%, about 99.7%, about 99.6%, about 99.5%, about 99.4%, about 99.3%, about 99.2%, about 99.1%, about 99%, about 98%, about 97%, about 96%, about 95%, about 94%, about 93%, about 92%, about 91%, about 90%, about 89%, about 88%, about 87%, about 86%, about 85%, about 84%, about 83%, about 82%, about 81%, about 80%, about 79%, about 78%, about 77%, about 76%, about 75%, about 74%, about 73%, about 72%, about 71%, about 70%, about 69%, about 68%, about 67%, about 66%, about 65%, about 64%, about 63%, about 62%, about 61%, about 60%, about 59%, about 58%, about 57%, about 56%, about 55%, about 54%, about 53%, about 5
- administration of the antibody, antibody fragment, or modification thereof decreases tumor cell viability at about 10 minutes to about 1 day after administration compared to the levels in a similar untreated subject or the same subject before administration of the antibody. In some embodiments, administration of the antibody, antibody fragment, or modification thereof decreases tumor cell viability at about 5 minutes, about 10 minutes, about 20 minutes, about 30 minutes, about 40 minutes, about 50 minutes, about 60 minutes, about 70 minutes, about 80 minutes, about 90 minutes, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, or about 24 hours after administration compared to the levels in a similar untreated subject or the same subject before administration of the antibody.
- administration of an antibody, antibody fragment, or modification thereof of the present disclosure decreases angiogenesis in a subject. In some embodiments, administration of the antibody, antibody fragment, or modification thereof decreases angiogenesis compared to the levels in a similar untreated subject or the same subject before administration of the antibody. In some embodiments, administration of the antibody, antibody fragment, or modification thereof decreases angiogenesis by about 99.9% to about 1% compared to the levels in a similar untreated subject or the same subject before administration of the antibody.
- administration of the antibody, antibody fragment, or modification thereof decreases angiogenesis by about 99.9%, about 99.8%, about 99.7%, about 99.6%, about 99.5%, about 99.4%, about 99.3%, about 99.2%, about 99.1%, about 99%, about 98%, about 97%, about 96%, about 95%, about 94%, about 93%, about 92%, about 91%, about 90%, about 89%, about 88%, about 87%, about 86%, about 85%, about 84%, about 83%, about 82%, about 81%, about 80%, about 79%, about 78%, about 77%, about 76%, about 75%, about 74%, about 73%, about 72%, about 71%, about 70%, about 69%, about 68%, about 67%, about 66%, about 65%, about 64%, about 63%, about 62%, about 61%, about 60%, about 59%, about 58%, about 57%, about 56%, about 55%, about 54%, about 53%, about 52%
- administration of the antibody, antibody fragment, or modification thereof decreases angiogenesis at about 10 minutes to about 1 day after administration compared to the levels in a similar untreated subject or the same subject before administration of the antibody.
- administration of the antibody, antibody fragment, or modification thereof decreases angiogenesis at about 5 minutes, about 10 minutes, about 20 minutes, about 30 minutes, about 40 minutes, about 50 minutes, about 60 minutes, about 70 minutes, about 80 minutes, about 90 minutes, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, or about 24 hours after administration compared to the levels in a similar untreated subject or the same subject before administration of the antibody.
- the subject has cancer.
- the angiogenesis is tumor-specific angiogenesis
- ADC Antibody-Drug Conjugate
- any of the provided anti-CD147 antibodies may be fused to a drug as part of an ADC.
- an antibody comprises any of the aforementioned constructs described in Table 1 or Table 2.
- Antibody-Drug Conjugates can be built by attaching a small molecule drug or another therapeutic agent to an antibody, with either a permanent or a labile linker. The antibody targets a specific antigen typically found on target cells. Once it binds to the cell, it triggers internalization of the antibody, together with the drug. This delivers drugs with a very high specificity to the diseased or target cells, maximizing their efficacy and minimizing systemic exposure, with the associated risk of side effects.
- a linker is utilized to connect an antibody with a drug.
- the linker is normally stabilized to avoid the release of the drug around off-target tissue, and the linker may maintain the conjugate in an inactive, nontoxic state while bound to the antibody.
- the linker should possess the property of unleashing the drug upon internalization of the ADC into a target cell.
- any of the linkers previously described can be utilized in an ADC construct.
- a drug that is part of an ADC is selected from the group consisting of an: anti-cancer drug, anti-malaria drug, anti-viral drug, an anti-inflammatory drug, and a toxin.
- the drug is an anti-viral drug.
- the anti -viral drug is an anti-SARS-CoV-2 drug.
- the anti-SARS-CoV-2 drug comprises a monoclonal antibody including but not limited to: bamlanivimab, etesevimab, casirivimab, imdevimab, and sotrovimab.
- an anti-SARS-CoV-2 drug is not an antibody.
- a drug is an anti-cancer drug.
- an anti-cancer drug comprises an immunotherapy.
- the immunotherapy is selected from the group consisting of an antibody, checkpoint inhibitor, cell therapy, cytokine, oncolytic virus, and vaccine.
- an anti-cancer drug comprises a cytotoxic agent.
- the immunotherapy comprises the antibody.
- Antibodies that are contemplated include gemtuzumab, inotuzumab, anti-B4-bR, denileukin, and combinations thereof.
- the drug comprises a toxin. Suitable toxins comprise pseudomonas exotoxin and/or diphtheria toxin.
- an ADC comprises the anti-CD147 antibody of SEQ ID NO: 14.
- an ADC comprises the anti-CD147 antibody of SEQ ID NO: 12.
- the drug comprises a growth factor.
- growth factors include but are not limited to: IL-2, IL- 13, TGFa, GM-CSF, and combinations thereof.
- the present disclosure provides methods of treating, ameliorating, or preventing a disorder associated with CD147 expression and/or a symptom thereof.
- the present disclosure provides methods of treating, ameliorating, or preventing cancer comprising administering pharmaceutical compositions of an anti-CD147 antibody, antibody fragment, or modification thereof of the disclosure to a subject in need.
- administration of an anti-CD147 antibody, antibody fragment, or modification thereof of the disclosure prevents or delays the growth of a tumor or proliferation of cancer cells in the subject.
- administration of an anti- CD 147 antibody, antibody fragment, or modification thereof of the disclosure prevents or delays the progression of cancer cells in the subject.
- administration of an anti-CD147 antibody, antibody fragment, or modification thereof of the disclosure prevents or delays cancer cell metastasis in the subject.
- administration of an anti- CD 147 antibody, antibody fragment, or modification thereof of the disclosure prevents or delays angiogenesis in the subject. In some embodiments, administration of an anti-CD 147 antibody, antibody fragment, or modification thereof of the disclosure prevents or delays cell invasion in the subject.
- the cancer includes, but is not limited to, breast cancer, lung cancer, prostate cancer, ovarian cancer, brain cancer, liver cancer, cervical cancer, colon cancer, renal cancer, skin cancer, head & neck cancer, bone cancer, esophageal cancer, bladder cancer, uterine cancer, lymphatic cancer, stomach cancer, pancreatic cancer, testicular cancer, leukemia, acute lymphocytic leukemia (ALL), acute myelogenous leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), and mantle cell lymphoma (MCL).
- ALL acute lymphocytic leukemia
- AML acute myelogenous leukemia
- CLL chronic lymphocytic leukemia
- CML chronic myelogenous leukemia
- MCL mantle cell lymphoma
- the present disclosure provides methods of treating, ameliorating, or preventing an inflammatory or autoimmune disorder comprising administering pharmaceutical compositions of an anti-CD147 antibody, antibody fragment, or modification thereof of the disclosure to a subject in need.
- the autoimmune or inflammatory disorder includes, but is not limited to, rheumatoid arthritis, systemic lupus erythematosus (SLE), celiac disease, inflammatory bowel disease, Hashimoto’s disease, Addison’s disease, Grave’s disease, type I diabetes, autoimmune thrombocytopenic purpura (ATP), idiopathic pulmonary fibrosis, idiopathic thrombocytopenia purpura (ITP), Crohn's disease, multiple sclerosis, and myasthenia gravis.
- the present disclosure provides a method of treating or preventing viral infection symptoms, and/or related conditions comprising administering a pharmaceutical composition comprising an anti-CD 147 antibody, antibody fragment, or modification thereof of the disclosure to a subject in need.
- the viral infection is caused by a virus including, but not limited to, measles, coronavirus, SARS, MERS, SARS-CoV-2, infectious hematopoietic necrosis virus (IHNV), parvovirus, Herpes Simplex Virus, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, mumps virus, rubella virus, HIV, Influenza virus, Rhinovirus, Rotavirus A, Rotavirus B, Rotavirus C, Respiratory Syncytial Virus (RSV), Varicella zoster, Poliovirus, immunodeficiency virus (e.g. HIV), enveloped virus, RNA virus, and hepatitis.
- a virus including, but not limited to, measles, coronavirus, SARS, MERS, SARS-CoV-2, infectious hematopoietic necrosis virus (IHNV), parvovirus, Herpes Simplex Virus, Hepatitis A virus, Hepatitis B virus
- the viral infection is a coronavirus infection.
- the coronavirus infection is a SARS-CoV-2 infection.
- Any strain of SARS-CoV-2 can be treated with the antibody of the disclosure including but not limited to: alpha, beta, gamma, delta, epsilon, zeta, eta, theta, iota, kappa, lambda, mu, nu, xi, omicron, pi, rho, sigma, tau, upsilon, phi, chi, psi, or omega.
- the SARS- CoV-2 strain is one or more of: Alpha, Beta, Gamma, Delta, and/or Omicron.
- the symptom and/or related condition is respiratory distress and/or failure.
- respiratory failure is defined based on resource utilization requiring at least one of the following: endotracheal intubation and mechanical ventilation, oxygen delivered by high-flow nasal cannula; heated, humidified, oxygen delivered via reinforced nasal cannula at flow rates > 20 L/min with fraction of delivered oxygen > 0.5, noninvasive positive pressure ventilation, extracorporeal membrane oxygenation (ECMO), and/or clinical diagnosis of respiratory failure (e.g. clinical need for one of the preceding therapies, but preceding therapies not able to be administered in settings of resource limitation).
- endotracheal intubation and mechanical ventilation oxygen delivered by high-flow nasal cannula
- heated, humidified oxygen delivered via reinforced nasal cannula at flow rates > 20 L/min with fraction of delivered oxygen > 0.5
- noninvasive positive pressure ventilation ECMO
- ECMO extracorporeal membrane oxygenation
- compositions including an anti- CD147 antibody, antibody fragment, or modification thereof of the disclosure with one or more pharmaceutically acceptable excipients and/or diluents.
- excipients include salts, and other excipients that may act to stabilize hydrogen bonding. Any appropriate excipient known in the art may be used.
- Exemplary excipients include, but are not limited to, amino acids such as histidine, glycine, or arginine; glycerol; sugars, such as sucrose; surface active agents such as polysorbate 20 and polysorbate 80; citric acid; sodium citrate; antioxidants; salts including alkaline earth metal salts such as sodium, potassium, and calcium; counter ions such as chloride and phosphate; preservatives; sugar alcohols (e.g., mannitol, sorbitol); and buffering agents.
- Exemplary salts include sodium chloride, potassium chloride, magnesium chloride, calcium chloride, sodium phosphate dibasic, sodium phosphate monobasic, potassium phosphate monobasic, and potassium phosphate dibasic.
- the pharmaceutical compositions disclosed herein have enhanced efficacy, bioavailability, therapeutic half-life, persistence, degradation resistance, etc.
- the pharmaceutical formulation can be stored frozen, refrigerated or at room temperature.
- the storage condition may be below freezing, such as lower than about -10°C, or lower than about -20°C, or lower than about -40°C, or lower than about -70°C.
- the pharmaceutical formulation is stored at 2°-8°C.
- the pharmaceutical formulation may be isotonic with blood or have an ionic strength that mimics physiological conditions.
- the formulation may have an ionic strength of at least that of 25 mM Sodium Chloride, or at least that of 30 mM Sodium chloride, or at least that of 40 mM Sodium Chloride, or at least that of 50 mM Sodium Chloride, or at least that of 75 mM Sodium Chloride, or at least that of 100 mM Sodium Chloride, or at least that of 150 mM Sodium Chloride.
- the formulation has an ionic strength equivalent to that of 0.9% saline (154 mM sodium chloride).
- the pharmaceutical formulation is formulated at physiological pH. In some embodiments, the pharmaceutical formulation is formulated at a pH in the range of about 5.5 to about 8.5. In some embodiments, the pharmaceutical formulation is formulated at a pH in the range of about 6.0 to about 8.0. In some embodiments, the pharmaceutical formulation is formulated at a pH in the range of about 6.5 to about 7.5. In some embodiments, the pharmaceutical formulation is formulated at a pH of 7.5. In some embodiments, pharmaceutical formulations with a lower pH demonstrate improved formulation stability compared to formulations at a higher pH. In some embodiments, pharmaceutical formulations with a higher pH demonstrate improved formulation stability compared to formulations at a lower pH.
- the pharmaceutical formulation is stable at storage conditions. Stability can be measured using any appropriate means in the art. Generally, a stable formulation is one that shows less than a 5% increase in degradation products or impurities. In some embodiments, the formulation is stable for at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, at least about one year, or at least about 2 years or more at the storage conditions. In some embodiments, the formulation is stable for at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, or at least about one year or more at 25 °C.
- the disclosure provides a method for delivering a pharmaceutical formulation disclosed herein.
- the method comprises administering the pharmaceutical formulation described herein to a subject in need, wherein the pharmaceutical formulation is administered from about 1 to about 31 times per month.
- the pharmaceutical formulation is administered about 1 time, about 2 times, about 3 times, and/or about 4 times per month.
- the pharmaceutical composition is administered daily.
- the pharmaceutical is administered weekly.
- the pharmaceutical composition is administered weekly.
- the pharmaceutical composition is administered from one to three times weekly.
- the pharmaceutical composition is administered once every two weeks.
- the pharmaceutical composition is administered from one to two times a month.
- the pharmaceutical composition is administered about 1 time per month.
- the pharmaceutical composition is administered about once every 2 months, about once every 3 months, about once every 4 months, about once every 5 months, and/or about once every 6 months.
- the pharmaceutical compositions disclosed herein are administered until at least one or more symptoms of the disorder being treated is reduced and/or improve. In some embodiments, the pharmaceutical compositions disclosed herein are administered until at least one or more symptoms is ameliorated. In some embodiments, the pharmaceutical compositions disclosed herein are administered until at least one or more symptoms thereof is delayed. In some embodiments, the pharmaceutical compositions disclosed herein are administered until the disorder is cured.
- the pharmaceutical compositions disclosed herein are administered before the patient begins to exhibit one or symptoms. In some embodiments, the pharmaceutical compositions disclosed herein are administered at the onset of symptoms. [0103]
- the pharmaceutical composition may be administered by any known route, such as for example, orally, intravenously, intramuscularly, nasally, subcutaneously, parenterally, via inhalation, or intradermally.
- the formulation is generally for subcutaneous administration. In some embodiments, the formulation is generally for intravenous administration.
- a suitable dose of the pharmaceutical composition for achievement of therapeutic benefit may, for example, be in a range of about 1 microgram (pg) to about 100 milligrams (mg) per kilogram body weight of the recipient, preferably in a range of about 10 pg to about 50 mg per kilogram body weight and most preferably in a range of about 100 pg to about 10 mg per kilogram body weight.
- the pharmaceutical composition is administered at a low dose.
- the pharmaceutical composition is administered at a dose between 0.1 mg per kilogram per body weight to about 9 mg per kilogram per body weight.
- the pharmaceutical composition is administered at about 0.05 mg per kilogram body weight, about 0.1 mg per kilogram body weight, about 0.2 mg per kilogram body weight, about 0.4 mg per kilogram body weight, about 0.5 mg per kilogram body weight, about 0.8 mg per kilogram body weight, about 1 mg per kilogram body weight, about 1.2 mg per kilogram body weight, about 2 mg per kilogram body weight, about 3 mg per kilogram body weight, and/or about 9 mg per kilogram body weight.
- the desired dose may be administered weekly.
- a suitable dose of the pharmaceutical composition for achievement of therapeutic benefit may, for example, be in a range of about 1 microgram (pg) to about 10 milligrams (mg) per kilogram body weight of the recipient, preferably in a range of about 10 pg to about 5 mg per kilogram body weight, and most preferably in a range of about 100 pg to about 2 mg per kilogram body weight.
- the pharmaceutical composition is administered at a low dose.
- the pharmaceutical composition is administered at a dose between 0.1 mg per kilogram per body weight to about 9 mg per kilogram per body weight.
- the pharmaceutical composition is administered at about 0.05 mg per kilogram body weight, about 0.1 mg per kilogram body weight, about 0.2 mg per kilogram body weight, about 0.4 mg per kilogram body weight, about 0.5 mg per kilogram body weight, about 0.8 mg per kilogram body weight, about 1 mg per kilogram body weight, about 1.2 mg per kilogram body weight, about 2 mg per kilogram body weight, about 3 mg per kilogram body weight, and/or about 9 mg per kilogram body weight.
- the desired dose may be presented as one dose, or two or more sub-doses administered at appropriate intervals.
- sub-doses can be administered in unit dosage forms, for example, containing from about 10 pg to about 1000 mg, preferably from about 50 pg to about 500 mg, and most preferably from about 50 pg to about 250 mg of active ingredient per unit dosage form.
- the doses may be administered as a continuous infusion.
- the pharmaceutical composition is administered in a fixed dose, regardless of the weight of the patient at a dose of about 1 mg to about lg or more. In some embodiments, the pharmaceutical composition is administered at a dose of about l.Omg, about l.lmg, about 1.2mg, about 1.3mg, about 1.4mg, about 1.5 mg, about 1.6mg, about 1.7mg, about 1.8mg, about 1.9mg, about 2.0mg, about 3.0mg, about 4.0mg, about 5.0mg, about 6.0mg, about 7.0mg, about 8.0mg, about 9.0mg, about lO.Omg, about 15mg, about 20mg, about 25mg, about 30mg, about 35mg, about 40mg, about 45mg, about 50mg, about 55mg, about 60mg, about 65mg, about 70mg, about 75mg, about 80mg, about 85mg, about 90mg
- the pharmaceutical composition is administered at a dose of about 10 mg, 40 mg, or 100 mg.
- the pharmaceutical composition may be administered for between about one day to about one year or more. In some embodiments, the pharmaceutical composition is administered for one day, two days, three days, four days, five days, six days, seven days, two weeks, three weeks, four weeks, one month, two months, three months, four months, five months, six months, seven months, eight months, nine months, ten months, eleven months, twelve months or more.
- the subject is a human, but in other embodiments may be anon-human mammal, such as a domesticated pet (e.g., dog or cat), or livestock or farm animal (e.g, horse, cow, sheep, or pig).
- a domesticated pet e.g., dog or cat
- livestock or farm animal e.g, horse, cow, sheep, or pig
- any appropriate subject may be administered the pharmaceutical compositions of the present disclosure.
- the subject is at risk of viral infection, development of cancer, or development of an autoimmune or inflammatory disorder.
- the patient is at risk of developing harmful or life-threatening effects of a disorder described herein.
- the subject is experiencing harmful or life- threatening effects of a disorder described herein.
- the subj ect is infected with, or presumed to be infected with, SARS-CoV-2.
- the subject has COVID-19, ARDS, and/or is experiencing symptoms associated with COVID-19 or ARDS.
- the subject is hospitalized.
- the patient has a mild case of COVID-19, ARDS, and/or is experiencing mild symptoms associated with COVID-19 or ARDS.
- the subject has a moderate case of COVID-19, ARDS, and/or is experiencing moderate symptoms associated with COVID-19 or ARDS.
- the subject has a severe case of COVID-19, ARDS, and/or is experiencing severe symptoms associated with COVID-19 (e.g., rapid clinical deterioration, ARDS, and/or death).
- the patient requires assistance breathing.
- the patient is receiving supplemental oxygen.
- the patient is receiving supplemental oxygen by face mask or nasal cannula with prongs.
- the patient requires a ventilator to breathe.
- the patient exhibits low oxygen saturation levels.
- the patient exhibits an increased respiratory rate (e.g., greater than 24 breaths/minute).
- the patient exhibits an accompanying fever (e.g., temperature greater than 100.4°F or 38°C).
- the patient is at risk of progressing to more severe COVID-19, ARDS, or symptoms thereof, and the pharmaceutical composition of the present disclosure is administered before symptoms worsen.
- the patient is determined as having mild COVID-19 by 1) positive testing by standard RT-PCR assay or the equivalent; 2) symptoms of mild illness with COVID-19 that could include fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, without shortness of breath of dyspnea; and/or 3) no clinical signs indicative of moderate, severe, or critical COVID-19.
- the patient is determined as having moderate COVID-19 by 1) positive testing by standard RT-PCR assay or the equivalent; 2) symptoms of moderate illness with COVID-19, which can include any symptom of mild illness or shortness of breath with exertion; 3) clinical signs suggestive of moderate illness with COVID-19, such as respiratory rate > 20 breaths per minute, saturation of oxygen (Sp02)> 93% on room air at sea level, heart rate > 90 beats per minute; and/or 4) no clinical signs indicative of severe or critical illness.
- the patient is determined as having severe COVID-19 by 1) positive testing by standard RT-PCR assay or the equivalent; 2) symptoms suggestive of severe systemic illness with COVID-19, which can include any symptom of moderate illness or shortness of breath at rest, or respiratory distress; 3) clinical signs indicative of severe systemic illness with COVID-19, such as respiratory rate > 30 per minute, heart rate >_ 125 per minute, SpC ⁇ 93% on room air at sea level, or PaC /FiC ⁇ 300 and/or 4) no criteria for critical severity.
- the patient is determined as having severe COVID-19 by 1) positive testing by standard RT-PCR assay or the equivalent; 2) evidence of critical illness, defined by at least one of the following: a) respiratory failure defined based on resource utilization requiring at least one of the following: endotracheal intubation and mechanical ventilation, oxygen delivered by high-flow nasal cannula; heated, humidified, oxygen delivered via reinforced nasal cannula at flow rates > 20 L/min with fraction of delivered oxygen > 0.5, noninvasive positive pressure ventilation, extracorporeal membrane oxygenation (ECMO), and/or clinical diagnosis of respiratory failure (e.g. clinical need for one of the preceding therapies, but preceding therapies not able to be administered in settings of resource limitation); b) shock (e.g.
- the patient is an infant (e.g., 0 to 2 years old inclusive). In some embodiments, the patient is a pediatric patient (e.g., 2 to 18 years old inclusive). In some embodiments the patient is between the ages of 18 and 100. In some embodiments, the patient is between the ages of 18 and 85. In some embodiments, the patient is between the ages of 50 and 100. In some embodiments, the patient is older than 65 years old.
- the patient is 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70 ,71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100 years old or older.
- the patient who is older than 50 years old is considered high risk of developing severe disease (e.g., COVID-19 or ARDS).
- the patient who is older than 65 years old is considered high risk of developing severe disease (e.g., COVID- 19 or ARDS).
- a patient who possesses one or more comorbidities is considered high risk for developing severe disease (e.g., COVID-19 or ARDS).
- the comorbidity includes, but is not limited to, obesity, hypertension, diabetes, an autoimmune disorder (e.g., rheumatoid arthritis), heart disease, heart failure, atherosclerosis, cancer (e.g., lung cancer), exposure to lung-damaging agents, liver disease, alcoholism, other pulmonary infection, and chronic kidney disease.
- the patient at risk presents with elevated markers of cardiac injury or dysfunction (e.g., hsTnl, NT-proBNP).
- race is a factor in a patient being considered at high risk of developing severe disease (e.g., COVID-19 or ARDS).
- socioeconomic status is a factor in a patient being considered at high risk of developing severe disease (e.g., COVID-19 or ARDS).
- the patient while being administered with a pharmaceutical composition of the present disclosure, the patient continues to receive standard of care for any comorbidities.
- compositions disclosed herein may be administered with various therapies used to treat, prevent, delay, or ameliorate cancers, viral infection, inflammation, autoimmune disorders, inflammatory lung damage, COVID-19, and/or ARDS.
- the pharmaceutical composition is administered concomitantly with standard of care medications.
- the one or more therapeutic agents may be any compound, molecule, or substance that exerts therapeutic effect to a subject in need thereof.
- the pharmaceutical compositions disclosed herein are administered with therapeutic agents including, but not limited to, antiviral agents, anti- malarial agents, agents that protect epithelial cells, defibrotide, convalescent plasma, chloroquine, hydroxychloroquine, remdesivir, desferal, favipiravir, corticosteroids, clevudine, anti-inflammatory agents, anti-oxidant agents, dapagliflozin, IFX-1, ruxolitinib, baricitinib, interferon beta la, azithromycin, tocilizumab, acalabrutinib, umifenovir, ciclesonide, sarilumab, anti-interleukin agents, and telmisartan.
- therapeutic agents including, but not limited to, antiviral agents, anti- malarial agents, agents that protect epithelial cells, defibrotide, convalescent plasma, chloroquine, hydroxychloroquine, remdesivir,
- a subject has previously been treated or undergoes combination therapy with an anti-SARS-CoV-2 therapy or COVID-19 therapy.
- Suitable therapies comprise: monoclonal antibodies (e.g., bamlanivimab, evusheld, sotrovimab, Regen- Cov, and etesevimab), Remdesivir, mechanical ventilation, oxygen therapy, and combinations thereof.
- a subject in need thereof is recalcitrant to an anti-SARS-CoV- 2 therapy or COVID-19 therapy for example those suitable therapies provided herein.
- a subject in need thereof that is recalcitrant to an anti-SARS-CoV-2 therapy is treated with an antibody of the disclosure.
- the pharmaceutical compositions disclosed herein are administered with one or more chemotherapeutic agents, including but not limited to, methotrexate, daunomycin, mitomycin, cisplatin, vincristine, epirubicin, fluorouracil, verapamil, cyclophosphamide, cytosine arabinoside, aminopterin, bleomycin, mitomycin C, democolcine, etoposide, mithramycin, chlorambucil, melphalan, daunorubicin, doxorubicin, tamoxifen, paclitaxel, vinblastine, camptothecin, actinomycin D, cytarabine, and combrestatin.
- chemotherapeutic agents including but not limited to, methotrexate, daunomycin, mitomycin, cisplatin, vincristine, epirubicin, fluorouracil, verapamil, cyclophosphamide, cytosine
- the one or more therapeutic agents may be “co-administered”, i.e., administered together in a coordinated fashion to a subject, either as separate pharmaceutical compositions or admixed in a single pharmaceutical composition.
- the one or more therapeutic agents may also be administered simultaneously with the present pharmaceutical compositions, or be administered separately, including at different times and with different frequencies.
- the one or more therapeutic agents may be administered by any known route, such as orally, intravenously, intramuscularly, nasally, via aerosol, subcutaneously, intra- vaginally, intra-rectally, and the like; and the therapeutic agent may also be administered by any conventional route.
- the pharmaceutical composition is administered subcutaneously.
- each therapeutic agent When two or more therapeutic agents are used in combination, the dosage of each therapeutic agent is commonly identical to the dosage of the agent when used independently. However, when a therapeutic agent interferes with the metabolism of others, the dosage of each therapeutic agent is properly adjusted. Alternatively, where the two or more therapeutic agents show synergistic effects, the dose of one or more may be reduced. Each therapeutic agent may be administered simultaneously or separately in an appropriate time interval.
- any concentration range, percentage range, ratio range or integer range is to be understood to be inclusive of the value of any integer within the recited range and, when appropriate, fractions thereof (such as one-tenth and one-hundredth of an integer), unless otherwise indicated.
- Units, prefixes, and symbols used herein are provided using their Systeme International de Unites (SI) accepted form. Numeric ranges are inclusive of the numbers defining the range.
- peptide refers to a compound comprising amino acid residues covalently linked by peptide bonds.
- a protein or peptide contains at least two amino acids, and no limitation is placed on the maximum number of amino acids that can comprise a protein's or peptide's sequence.
- Polypeptides include any peptide or protein comprising two or more amino acids joined to each other by peptide bonds.
- the term refers to both short chains, which also commonly are referred to in the art as peptides, oligopeptides and oligomers, for example, and to longer chains, which generally are referred to in the art as proteins, of which there are many types.
- Polypeptides include, for example, biologically active fragments, substantially homologous polypeptides, oligopeptides, homodimers, heterodimers, variants of polypeptides, modified polypeptides, derivatives, analogs, fusion proteins, among others.
- the polypeptides include natural peptides, recombinant peptides, synthetic peptides, or a combination thereof.
- percent identity To calculate percent identity, the sequences being compared are typically aligned in a way that gives the largest match between the sequences.
- GCG program package which includes GAP (Devereux et ak, 1984, Nucl. Acid Res.
- the computer algorithm GAP is used to align the two polypeptides or polynucleotides for which the percent sequence identity is to be determined. The sequences are aligned for optimal matching of their respective amino acid or nucleotide (the "matched span,” as determined by the algorithm).
- a standard comparison matrix see, Dayhoff et ak, 1978, Atlas of Protein Sequence and Structure 5 :345-352 for the PAM 250 comparison matrix; Henikoff et ak, 1992, Proc. Natl. Acad. Sci. U. S.A. 89: 10915-10919 for the BLOSUM 62 comparison matrix is also used by the algorithm.
- Embodiments of the present subject matter disclosed herein may be beneficial alone or in combination with one or more other embodiments. Without limiting the foregoing description, certain non-limiting embodiments of the disclosure are provided below. As will be apparent to those of skill in the art upon reading this disclosure, each of the individually numbered embodiments may be used or combined with any of the preceding or following individually numbered embodiments. This is intended to provide support for all such combinations of embodiments and is not limited to combinations of embodiments explicitly provided below.
- Embodiment 1 An anti-CD 147 antibody comprising a binding domain that comprises at least one CDR comprising at least 70% identity to an amino acid sequence selected from SEQ ID NOs: 16-39.
- Embodiment 2 The anti-CD 147 antibody of embodiment 1, wherein the anti- CD147 antibody comprises two CDRs, wherein each of the two CDRs independently comprise at least 70% identity to an amino acid sequence selected from SEQ ID NOs: 16-39.
- Embodiment 3 The anti-CD 147 antibody of embodiments 1 or 2, wherein the anti- CD 147 antibody comprises three CDRs, wherein each of the three CDRs independently comprise at least 70% identity to an amino acid sequence selected from SEQ ID NOs: 16-39.
- Embodiment 4 The anti-CD147 antibody of any one of embodiments 1-3, wherein the anti-CD 147 antibody comprises an amino acid sequence with at least 70% identity to a sequence selected from SEQ ID NOs: 4-15.
- Embodiment 5 The anti-CD 147 antibody of any one of embodiments 1-4, wherein the anti-CD147 antibody comprises an amino acid sequence selected from SEQ ID NOs: 4-15.
- Embodiment 6. The anti-CD147 antibody of any one of embodiments 1-5, wherein the antibody is a full-length antibody, a monospecific antibody, a bispecific antibody, a trispecific antibody, an antigen-binding region, heavy chain, light chain, VhH, Vh, a CDR, a variable domain, scFv, Fc, Fv, Fab, F(ab)2, IgG, reduced IgG (rlgG), monospecific Fab2, bispecific Fab2, trispecific Fab3, diabody, bispecific diabody, trispecific triabody, minibody, nanobody, IgNAR, V-NAR, HcIgG, or a combination thereof.
- Embodiment 7 The anti-CD 147 antibody of embodiment 6, wherein the antibody is the VhH.
- Embodiment 8 The anti-CD147 antibody of any one of embodiments 1-7, wherein a binding region of a Chimeric Antigen Receptor (CAR) comprises at least one CDR comprising at least 70% identity to an amino acid sequence selected from SEQ ID NOs: 16- 39.
- CAR Chimeric Antigen Receptor
- Embodiment 9 The anti-CD147 antibody of embodiment 8, wherein the CAR is expressed on an immune cell.
- Embodiment 10 The anti-CD147 antibody of embodiment 9, wherein the immune cell is a peripheral blood mononuclear cell (PBMC), a lymphocyte, a T cell, or a NK cell.
- PBMC peripheral blood mononuclear cell
- Embodiment 11 The anti-CD147 antibody of any one of embodiments 1-10, wherein the anti-CD147 antibody binds to a CD147 or fragment thereof expressed on the surface of a cell.
- Embodiment 12 The anti-CD147 antibody of embodiment 11, wherein the cell is an epithelial cell, an endothelial cell, or neuronal cell.
- Embodiment 13 The anti-CD 147 antibody of any one of embodiments 1-12, wherein the anti-CD 147 antibody reduces or eliminates interaction between a virus and CD 147.
- Embodiment 14 The anti-CD147 antibody of embodiment 13, wherein the interaction comprises binding of the CD147 by the virus.
- Embodiment 15 The anti-CD 147 antibody of any one of embodiments 1-14, wherein the anti-CD 147 antibody reduces or eliminates a viral spike protein from binding to CD147.
- Embodiment 16 The anti-CD147 antibody of any one of embodiments 1-15, wherein the anti-CD 147 antibody reduces or eliminates viral invasion of a cell.
- Embodiment 17 The anti-CD147 antibody of any one of embodiments 1-16, wherein the anti-CD 147 antibody reduces or eliminates viral invasion of a cell by at least about 1-fold as determined by a viral infectivity assay.
- Embodiment 18 The anti-CD147 antibody of any one of embodiments 13-17, wherein the virus is selected from the group consisting of: measles, coronavirus, S ARS, MERS, infectious hematopoietic necrosis virus (IHNV), parvovirus, Herpes Simplex Virus, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, mumps virus, rubella virus, HIV, Influenza virus, Rhinovirus, Rotavirus A, Rotavirus B, Rotavirus C, Respiratory Syncytial Virus (RSV), Varicella zoster, Poliovirus, immunodeficiency virus (e.g. HIV), enveloped virus, RNA virus, and hepatitis.
- the virus is selected from the group consisting of: measles, coronavirus, S ARS, MERS, infectious hematopoietic necrosis virus (IHNV), parvovirus, Herpes Simplex Virus, Hepatitis A virus,
- Embodiment 19 The anti-CD 147 antibody of embodiment 18, wherein the virus is the coronavirus.
- Embodiment 20 The anti-CD147 antibody of embodiment 19, wherein the coronavirus is SARS-CoV-2.
- Embodiment 21 The anti-CD147 antibody of any one of embodiments 11-20, wherein the cell is a cancer cell.
- Embodiment 22 The anti-CD147 antibody of any one of embodiments 11-20, wherein the cell is a tumor cell.
- Embodiment 23 The anti-CD 147 antibody of embodiment 21, wherein the cancer cell is from a hematological cancer.
- Embodiment 24 The anti-CD147 antibody of embodiment 22, wherein the tumor cell is from a cancer selected from the group consisting of: breast cancer, lung cancer, prostate cancer, ovarian cancer, brain cancer, liver cancer, cervical cancer, colon cancer, renal cancer, skin cancer, head & neck cancer, bone cancer, esophageal cancer, bladder cancer, uterine cancer, lymphatic cancer, stomach cancer, pancreatic cancer, testicular cancer, leukemia, acute lymphocytic leukemia (ALL), acute myelogenous leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), and mantle cell lymphoma (MCL).
- ALL acute lymphocytic leukemia
- AML acute myelogenous leukemia
- CLL chronic lymphocytic leukemia
- CML chronic myelogenous leukemia
- MCL mantle cell lymphoma
- Embodiment 26 The anti-CD 147 antibody of any one of embodiments 1-24, wherein the anti-CD 147 antibody reduces or eliminates inflammation.
- Embodiment 27 The anti-CD147 antibody of any one of embodiments 1-24, wherein the anti-CD147 antibody is effective in reducing or eliminating an inflammatory or autoimmune disorder.
- Embodiment 28 The anti-CD 147 antibody of embodiment 27, wherein the inflammatory or autoimmune disease is selected from the group consisting of: rheumatoid arthritis, systemic lupus erythematosus (SLE), celiac disease, inflammatory bowel disease, Hashimoto’s disease, Addison’s disease, Grave’s disease, type I diabetes, autoimmune thrombocytopenic purpura (ATP), idiopathic pulmonary fibrosis, idiopathic thrombocytopenia purpura (ITP), Crohn's disease, multiple sclerosis, and myasthenia gravis.
- Embodiment 29 The anti-CD147 antibody of any one of embodiments 1-28, wherein the anti-CD 147 antibody is humanized.
- Embodiment 30 A method of preventing, treating, or ameliorating a disorder associated with CD 147 expression in a subject in need thereof comprising administering the anti-CD 147 antibody of any one of embodiments 1-29.
- Embodiment 31 A pharmaceutical composition comprising an effective amount of the anti-CD 147 antibody of any one of embodiments 1-29.
- Embodiment 32 A cell comprising a sequence encoding the anti-CD 147 antibody of any one of embodiments 1-29.
- Embodiment 33 The anti-CD 147 antibody of any one of embodiments 1-29, wherein the anti-CD 147 antibody binds to a cell thereby preventing, inhibiting, or decreasing invasion of a Plasmodium parasite into the cell.
- Embodiment 34 The anti-CD 147 antibody of embodiment 33, wherein the invasion of the Plasmodium parasite into the cell is by at least about 1-fold.
- Embodiment 35 The anti-CD 147 antibody of embodiment 34, wherein the cell is a red blood cell.
- Embodiment 36 The anti-CD147 antibody of any one of embodiments 33-35, wherein the Plasmodium parasite is selected from the group consisting of: Plasmodium falciparum, Plasmodium malariae, Plasmodium ovale, Plasmodium vivax, and Plasmodium knowlesi.
- Embodiment 37 The anti-CD147 antibody of any one of embodiments 33-36, wherein the anti-CD 147 antibody is effective in decreasing parasitemia in blood cells.
- Embodiment 38 The anti-CD147 antibody of embodiment 37, wherein the anti- CD147 antibody decreases parasitemia in blood cells within about 48 hours.
- Embodiment 39 The anti-CD147 antibody of embodiment 37, wherein the anti- CD147 antibody decreases parasitemia in blood cells within about 96 hours.
- Embodiment 40 The anti-CD147 antibody of embodiment 33, wherein administration of the anti-CD 147 antibody prevents, ameliorates, or treats malaria in a subject.
- Embodiment 41 An anti-CD147 antibody that comprises a CDR1, a CDR2, and a CDR3 region, wherein the CDR1 region is an amino acid sequence selected from the group consisting of: SEQ ID NO: 16-SEQ ID NO: 23, wherein the CDR2 region is an amino acid sequence selected from the group consisting of: SEQ ID NO: 24-SEQ ID NO: 31, wherein the CDR3 region is an amino acid sequence selected from the group consisting of: SEQ ID NO: 32-SEQ ID NO: 39, and wherein the anti-CD 147 antibody comprises from 0 to 5 amino acid modifications in at least one of the CDR1, CDR, or CDR3 regions.
- Embodiment 42 The anti-CD147 antibody of embodiment 41, wherein the anti- CD147 antibody comprises from 0-3 amino acid modifications.
- Embodiment 43 The anti-CD 147 antibody of any one of embodiments 41-42, wherein the CDR1 region corresponds to SEQ ID NO: 18 or 22, wherein the CDR2 region corresponds to SEQ ID NO: 26 or 30, and wherein the CDR3 region corresponds to SEQ ID NO: 34 or 38.
- Embodiment 44 The anti-CD147 antibody of any one of embodiments 41-43, wherein the anti-CD147 antibody comprises SEQ ID NO: 12 or SEQ ID NO: 14.
- Embodiment 45 The anti-CD147 antibody of anyone of embodiments 41-44, wherein the anti-CD 147 antibody is humanized.
- Embodiment 46 A method of treatment, comprising administering an effective amount of a pharmaceutical composition comprising an anti-CD147 antibody, wherein the anti- CD 147 antibody comprises a CDR1, a CDR2, and a CDR3 region, wherein the CDR1 region is an amino acid sequence selected from the group consisting of: SEQ ID NO: 16-SEQ ID NO: 23, wherein the CDR2 region is an amino acid sequence selected from the group consisting of: SEQ ID NO: 24-SEQ ID NO: 31, wherein the CDR3 region is an amino acid sequence selected from the group consisting of: SEQ ID NO: 32-SEQ ID NO: 39, and wherein the anti-CD147 antibody comprises from 0 to 2 amino acid modifications in at least one of the CDR1, CDR, or CDR3 regions.
- Embodiment 47 The method of treatment of embodiment 46, wherein the administering is effective in reducing or eliminating an inflammatory or autoimmune disease.
- Embodiment 48 The method of treatment of any one of embodiments 46-47, wherein the inflammatory or autoimmune disease is selected from the group consisting of: rheumatoid arthritis, systemic lupus erythematosus (SLE), celiac disease, inflammatory bowel disease, Hashimoto’s disease, Addison’s disease, Grave’s disease, type I diabetes, autoimmune thrombocytopenic purpura (ATP), idiopathic pulmonary fibrosis, idiopathic thrombocytopenia purpura (ITP), Crohn's disease, multiple sclerosis, and myasthenia gravis.
- SLE systemic lupus erythematosus
- ATP autoimmune thrombocytopenic purpura
- IDP idiopathic pulmonary fibrosis
- IDP idi
- Embodiment 49 The method of treatment of any one of embodiments 46-48, wherein the administering is effective in reducing or eliminating viral invasion of a cell by a virus.
- Embodiment 50 The method of treatment of embodiment 49, wherein the virus is selected from the group consisting of: measles, coronavirus, SARS, MERS, infectious hematopoietic necrosis virus (IHNV), parvovirus, Herpes Simplex Virus, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, mumps virus, rubella virus, HIV, Influenza virus, Rhinovirus, Rotavirus A, Rotavirus B, Rotavirus C, Respiratory Syncytial Virus (RSV), Varicella zoster, Poliovirus, immunodeficiency virus (e.g. HIV), enveloped virus, RNA virus, and hepatitis.
- the virus is selected from the group consisting of: measles, coronavirus, SARS, MERS, infectious hematopoietic necrosis virus (IHNV), parvovirus, Herpes Simplex Virus, Hepatitis A virus, Hepatitis B virus, Hepati
- Embodiment 51 The method of treatment of embodiment 50, wherein the virus is the coronavirus.
- Embodiment 52 The method of treatment of embodiment 51, wherein the coronavirus comprises SARS-CoV-2.
- Embodiment 53 The method of treatment of any one of embodiments 46-48, wherein the administering is effective in reducing or eliminating metastasis of a cancer.
- Embodiment 54 The method of treatment of embodiment 53, wherein the cancer is selected from the group consisting of breast cancer, lung cancer, prostate cancer, ovarian cancer, brain cancer, liver cancer, cervical cancer, colon cancer, renal cancer, skin cancer, head & neck cancer, bone cancer, esophageal cancer, bladder cancer, uterine cancer, lymphatic cancer, stomach cancer, pancreatic cancer, testicular cancer, leukemia, acute lymphocytic leukemia (ALL), acute myelogenous leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), and mantle cell lymphoma (MCL).
- ALL acute lymphocytic leukemia
- AML acute myelogenous leukemia
- CLL chronic lymphocytic leukemia
- CML chronic myelogenous leukemia
- MCL mantle cell lymphoma
- Embodiment 56 An antibody-drug conjugate that comprises the anti-CD147 antibody of any one of embodiments 1-29.
- Embodiment 57 The antibody-drug conjugate of embodiment 56, wherein the drug is selected from the group consisting of an: anti-cancer drug, anti-malaria drug, anti-viral drug, and an anti-inflammatory drug.
- Embodiment 58 The antibody-drug conjugate of embodiment 57, comprising the anti-viral drug, wherein the anti-viral drug is an anti-SARS-CoV-2 drug.
- Embodiment 59 The antibody-drug conjugate of embodiment 57, comprising the anti-cancer drug, wherein the anti-cancer drug comprises an immunotherapy.
- Embodiment 60 The antibody-drug conjugate of embodiment 59, wherein the immunotherapy is selected from the group consisting of an antibody, checkpoint inhibitor, cell therapy, cytokine, oncolytic virus, and vaccine.
- Embodiment 61 The antibody-drug conjugate of embodiment 60, comprising the antibody.
- Embodiment 62 The antibody-drug conjugate of embodiment 56, wherein the anti- CD147 antibody comprises SEQ ID NO: 12 or SEQ ID NO: 14. EXAMPLES
- VhH antibodies that bind human CD147 a llama was immunized with recombinant CD 147 (in a cocktail of 21 antigens) and boosted four times. mRNA was extracted from blood lymphocytes, and a VhH antibody display library was constructed in a yeast surface expression system. Yeast clones expressing anti-CD147 VhH antibodies were enriched by two rounds of panning and FACS, and twenty-four were analyzed for VhH secretion. Their anti- CD147 activity was measured by ELISA.
- Ibx-11, Ibx- 13, Ibx-75, Ibx-76, Ibx-77, and anti-HIS antibody was incubated at 0.01 - 100 ng/well in IOOmI for 1 hour at RT before being washed 3X for 5 min each wash.
- the wells were incubated with anti human for Ibx-11 & Ibx-13 treated wells and with anti-flag for Ibx-77, Ibx-75, Ibx-76 treated antibodies at 1 : 1000 dilution for 1 hour RT, and then washed 3x for 5min each wash.
- the improved binding of the IgG Fc fusions over the tandem bivalents may be due to different secondary reagents used (anti-Fc vs anti-Flag, respectively), or differences in functional valency (i.e., the tandem bivalent constructions may be effectively binding as a monovalent structure due to short linker length).
- ELISA For the ELISA, 100 ng of murine CD147 was coated onto Nunc polysorb plates overnight in lx coating buffer. The wells were washed once with TBST (0.01% tween 20) and then blocked for 1 hour using lx fishgel in TBST at room temperature (RT). Ibx-11, Ibx-13, Ibx-75, Ibx-76, Ibx-77, and anti-HIS antibody was incubated at 0.01 - 100 ng/well in IOOmI for 1 hour at RT before being washed 3X for 5 min each wash.
- CD147 was injected in HBS-EP buffer pH7.4 at concentrations ranging from 0 nM to 900nM at IOmI/min for 600 Seconds. Duplicate CD147 injections were carried out for 0, 9.22, 0, 23.04, 57.6, 144, 360, 900nM (a 2.5-fold dilution series). The chip surface was regenerated using 10 mM Glycine pH 2.0 @ IOmI/min for 180 sec.
- KD 36.1 nM ( ⁇ 0.001 nM).
- Example 4 SPR Analysis ofIbx-77 Binding to CD 147 on CMD Chip
- the CMD chip surface was activated by injecting 1 : 1 mixture of NHS/EDC for 420 sec at IOmI/min. 100pg/ml CD147 was immobilized with lOmM Sodium Acetate solution pH4.5 at 10m1 /min for 510 sec. The unreacted CD147 and activated chip surface were washed and inactivated by ethanolamine pH8.5 at 10m1/ min for 420 sec. A total of approx. 3800 RU of CD 147 was immobilized.
- Ibx - 77 was injected in HBS-EP buffer pH 7.4 at concentrations ranging from 9.22 nM to 360nM at IOmI/min for 420 sec.
- the chip surface was regenerated using 10 mM Glycine pH 2.0
- Example 5 Ibx-77 binds to HEK 293 and HCC 1954 cells
- Negative cells were gated out based on the unstained cells for individual cell line.
- Conditions for each cell line CST for positive control only; Ibx-77 only; ISO type controls rabbit; UST; Anti-Flag 4882° only - XF2.
- Ibx-77-stained cells show positive stained cell populations that are distinct from unstained controls in the HEK 293 cells ( Figure 8) and HCC 1954 ( Figure 9) cell lines.
- Example 6 Ibx-77 binds to CD147 expressed on HeLa cells
- HELA cell lines were grown to confluency in recommended medium in T-75 flask. Approximately 1 million cells were plated on to 6 well plates and were allowed to settle and grow overnight. Cells were lifted by manual scrapping with wide blunt mouth end of 1ml pipette tip and Cells were prepared for flow cytometry analysis as before. Cells were washed once in flow sauce, incubated in 1 pi/ ml viability dye 660 for 30 minutes on ice, then washed 2 times. 10 pg and 5 pg of Ibx-77 were used for staining cells, for 1 hour on ice, followed by 2x washes.
- Example 7 Analysis of the ability of Ibx-77, Ibx-13, andlbx-ll to bind to cells
- HeLa and HCC-1954 cell lines were grown to confluency in recommended medium in T-75 flask. Approximately 1 million cells were plated on to 6 well plates and were allowed to settle and grow overnight. Cells were lifted by manual scrapping with wide blunt mouth end of lml pipette tip and Cells were prepared for flow cytometry analysis as before. Cells were washed once in flow sauce (PBS, 1% FBS and Na Azide). Incubated in lpl/ ml viability dye 660 for 30 min on ice, then washed twice.
- flow sauce PBS, 1% FBS and Na Azide
- Example 8 Analysis of the ability of Ibx-11 and Ibex-13 antibodies to bind to Jurkat T-cells
- Jurkat cells were grown to confluency in recommended medium, and approximately 4 million cells were collected and prepared for flow cytometry analysis as before. These cells were not Na Azide-treated. The cells were washed once in flow sauce (PBS, 1% FBS and Na Azide) before incubation in lpl/mL viability dye 660 for 30 minutes on ice and washed twice. One pg/100pl of Fc bloc reagent was used to block Fc receptors for 10 minutes at room temperature, followed by two washes.
- flow sauce PBS, 1% FBS and Na Azide
- the cells were stained with antibodies in the indicated quantities as shown in the table in Figure 13 for one hour on ice, followed by two washes.
- the designated tubes were incubated with spike RBD (1 pg/tube) for one hour and then washed twice.
- the cells were then incubated with anti-spike antibody, VhH-Fc control, human isotype antibody or Ibx-11 for one hour at 4°C, and then washed twice.
- the cells were then incubated for 30 minutes with anti-human Dylight488 and then anti-rabbit Dylight488 followed by two washes.
- the cells were resuspended in lOOOpl of flow sauce for a final run on the flow cytometer. 50,000 total events were collected for analysis wherever possible within 300 seconds (5 minutes). Negative cells were gated out based on the VhH- Fc(h27-8GL) cells for individual cell lines.
- Example 9 Analysis of the ability of Ibx-11 and Ibex-13 antibodies to bind to Vero E-6 cells
- Jurkat and Vero E-6 cells were grown to confluency in recommended medium. Approximately 1 million cells per well were plated on a 6 well-dish and were prepare for flow cytometry analysis as before. The cells were not Na- Azide treated. The cells were washed once in flow sauce (PBS, 1% FBS, and Na Azide). One pg/100pl of Fc bloc reagent was used to block the Fc receptors for 10 minutes at room temperature, followed by two washes. The cells were stained with antibodies in the indicated quantities as shown in the table in Figure 14A-B for one hour on ice, followed by two washes.
- the Vero E6 cells were analyzed using the same voltage settings on the flow cytometer that were set for Jurkat Cells.
- Jurkat cells show good staining with Ibx-11, Ibx-13 and Ibx-77 with distinct separation between the negative (VhH-Fc-(h27-8GL) and unstained controls.
- Figure 14A Surprisingly, the Vero E6 cells show that Ibx-13 stains stronger than Ibx-11. See Figure 14B.
- Such differences in amino acids may be part of the critical epitopes for the Ibx antibody series and can used for potential epitope mapping.
- Ibx-13 and its dimerized version Ibx-76 may be good candidates.
- Ibx-77 showed two peak populations that may indicate weaker staining on the Vero E6 cells.
- MiaPaCa-2 cancer cells were seeded 2500 cells/well in a 96 well dish, allowed to adhere, and grown overnight. Old medium was replaced with 50 m ⁇ of fresh medium.
- Ibx-11 and Ibx-13 were prepared by premixing the antibody with anti-human IgG Fc-MMAF. Fifty microliters of the Ibx-11 and Ibx-13 mixtures in various concentrations (final concentrations of 30 nM to 1.1 nM) was added to the wells. Isotype and secondary ADC only controls were included on the plates. The plates were then incubated for 72 hours. After this 72-hour incubation, the viability of the cells was measured using Rockland Kit.
- Ibx-11 and Ibx-13 showed about 73% and 74% viable cells respectively. See Figure 16. These antibodies effectively killed the cancer cells.
- Jurkat T-cells were plated at 20,000 cells/well in a 96 round bottom well in IOOmI. 100mg/ml of Ibx-77, Ibx-11, or Ibx-13 were added to the cells in IOOmI to a final volume of 200 m ⁇ per well and a final concentration of 50 pg/ml antibodies. Images were collected at 0 hours, 2 hours, 4 hours, 9 hours, 18 hours, and 24 hours. ImageJ was used for measuring pixel 2 hours and reached a maximum at 24 hours. No further differences were noticed at 48 hours.
- Figure 17 shows differences in the pattern of aggregation was evident at 18 hours, with cells treated with an Ibx series antibody at 50 pg/ml showing distinct aggregation patterns with tighter clusters of aggregates and fewer individual cells, compared to untreated control A similar pattern was observed with the anti-CD 147 control antibody and the anti-CD98 antibody at lower doses of 20 pg/ml. These data were also analyzed quantitatively with imaging analysis which counts the pixel size from an 8-bit image. 50pg/ml - 25 pg/ml Ibx-series antibodies show larger pixel sizes for the particles (aggregates) at 24 hours. These differences are subtle between Ibx-series antibodies. See Figure 18.
- Example 13- Ibx-76 and Ibx-77 inhibit angiogenesis in tubule formation assay [0227] The ability of the anti-CD 147 VhH antibodies to inhibit angiogenesis was explored using a tubule formation assay.
- HuVEC cells were seeded onto the surface of Matrigel coated wells.
- Antibodies and CD 147 protein (added for competition) were added the day after seeding. After an additional day of culture, cells were stained with Calcein AM. Tube formation was then assessed by microscopy.
- a mouse antibody that binds human CD147 (HIM6) was used here as a positive control.
- Example 14 Ibx-13 prevents growth of Plasmodium falciparum in blood cells [0229] The ability of different antibodies to block the growth of the NF54 strain of Plasmodium falciparum in red blood cells. The initial parasitemia was 1.3% and the strain was cultured at 2% hematocrit in a 96-well plate. The Ibx-13 or MIF-2-5 antibodies or VhH-Fc were administered to the wells at 1, 10, and 100 pg/mL. Parasites not exposed to any antibody were cultured as the negative control, and the parasites cultured with the anti-malarial agent chloroquine (CQ) were used as the positive control.
- CQ chloroquine
- Blood smears were prepared at 48- and 96- hours post-treatment, stained, and ready by microscopy in a blinded manner.
- the number of infected red blood cells (RBCs) were scored in a blinded manner out of approximately 1000 red blood cells and expressed as a percentage parasitemia.
- Example 15 Antibody Drug Conjugate Assay on Malignant Melanoma Cells
- 2,500 A375 (malignant melanoma) cells were plated per well in a 96-well plate in complete growth medium (DMEM, 10% FBS) and were allowed to adhere overnight. The next day, the old medium was replenished with 50 pi of fresh complete media and 25 pi of the Ibx- 11, Ibx-13, or control antibodies (diluted in complete media). The antibodies were added in amounts ranging from 30nM to 1. InM in 3-fold decreasing concentrations while the secondary ADC was kept constant at 30nM. These mixtures were allowed to incubate for 5 minutes.
- A375 cells show sensitivity to increasing doses up to 3.3 nM of the Primary antibodies Ibx-11 and Ibx-13. See Figures 24-25. The maximum effect observed was -55% loss of viability at 3.3nM, with viability then tapering off at higher antibody concentrations. The secondary ADC itself at 30 nM may have a small effect compared to the untreated cells. Some effect of human isotype controls was also observed.
- Example 16 Antibody Drug Conjugate Assay on Prostate Cancer Cells 2,500 PC-3 (prostate cancer) cells were plated per well in a 96-well plate in complete growth medium (F-12K, 10% FBS) and were allowed to adhere overnight. The next day, the old medium was replenished with 50 pi of fresh complete media and 25 m ⁇ of the Ibx- 11, Ibx-13, or control antibodies (diluted in complete media). The antibodies were added in amounts ranging from 30nM to 1. InM in 3-fold decreasing concentrations while the secondary ADC was kept constant at 30nM. These mixtures were allowed to incubate for 5 minutes.
- complete growth medium F-12K, 10% FBS
- the PC3 cells may be less susceptible to the ADC assay than the A375 (malignant melanoma) cells taught in Example 15. See Figures 26 and 27. The maximum effect observed here was about a 25% loss of viability. This difference in viability may be due to the amount of surface CD 147 present on the cells and the corresponding differences in the rate of endocytosis and the susceptibility of the cancer to the toxic payload used in the assay.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023541593A JP2024503374A (en) | 2021-01-11 | 2022-01-11 | Antibodies targeting CD147 |
EP22737289.3A EP4274615A4 (en) | 2021-01-11 | 2022-01-11 | ANTIBODIES AGAINST CD147 |
IL304093A IL304093A (en) | 2021-01-11 | 2022-01-11 | Antibodies targeted to cd147 |
AU2022205427A AU2022205427A1 (en) | 2021-01-11 | 2022-01-11 | Antibodies targeted to cd147 |
CA3204047A CA3204047A1 (en) | 2021-01-11 | 2022-01-11 | Antibodies targeted to cd147 |
KR1020237026611A KR20230131478A (en) | 2021-01-11 | 2022-01-11 | Antibodies targeting CD147 |
CN202280014184.XA CN116887861A (en) | 2021-01-11 | 2022-01-11 | Antibodies targeting CD147 |
US18/347,295 US20240010723A1 (en) | 2021-01-11 | 2023-07-05 | Antibodies targeted to cd147 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163135827P | 2021-01-11 | 2021-01-11 | |
US63/135,827 | 2021-01-11 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/347,295 Continuation US20240010723A1 (en) | 2021-01-11 | 2023-07-05 | Antibodies targeted to cd147 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022150759A1 true WO2022150759A1 (en) | 2022-07-14 |
Family
ID=82357136
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2022/011969 WO2022150759A1 (en) | 2021-01-11 | 2022-01-11 | Antibodies targeted to cd147 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20240010723A1 (en) |
EP (1) | EP4274615A4 (en) |
JP (1) | JP2024503374A (en) |
KR (1) | KR20230131478A (en) |
CN (1) | CN116887861A (en) |
AU (1) | AU2022205427A1 (en) |
CA (1) | CA3204047A1 (en) |
IL (1) | IL304093A (en) |
WO (1) | WO2022150759A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN119462935A (en) * | 2025-01-15 | 2025-02-18 | 百吉生物医药(广州)股份有限公司 | A pan-tumor antigen antibody D6 and its application |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN119462934B (en) * | 2025-01-15 | 2025-03-21 | 百吉生物医药(广州)股份有限公司 | A pan-tumor antigen antibody D2 and its application |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008142164A2 (en) * | 2007-05-24 | 2008-11-27 | Ablynx N.V. | Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders |
US20180303952A1 (en) * | 2017-03-09 | 2018-10-25 | Cytomx Therapeutics, Inc. | Cd147 antibodies, activatable cd147 antibodies, and methods of making and use thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107629125B (en) * | 2017-09-07 | 2019-10-15 | 北京大学 | A kind of anti-CD147 nanobody, its production method and application |
CN107663237B (en) * | 2017-09-07 | 2019-10-15 | 北京大学 | A kind of anti-CD147 antibody and its production method and application |
-
2022
- 2022-01-11 CN CN202280014184.XA patent/CN116887861A/en active Pending
- 2022-01-11 WO PCT/US2022/011969 patent/WO2022150759A1/en active Application Filing
- 2022-01-11 EP EP22737289.3A patent/EP4274615A4/en active Pending
- 2022-01-11 CA CA3204047A patent/CA3204047A1/en active Pending
- 2022-01-11 IL IL304093A patent/IL304093A/en unknown
- 2022-01-11 AU AU2022205427A patent/AU2022205427A1/en active Pending
- 2022-01-11 KR KR1020237026611A patent/KR20230131478A/en active Pending
- 2022-01-11 JP JP2023541593A patent/JP2024503374A/en active Pending
-
2023
- 2023-07-05 US US18/347,295 patent/US20240010723A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008142164A2 (en) * | 2007-05-24 | 2008-11-27 | Ablynx N.V. | Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders |
US20180303952A1 (en) * | 2017-03-09 | 2018-10-25 | Cytomx Therapeutics, Inc. | Cd147 antibodies, activatable cd147 antibodies, and methods of making and use thereof |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN119462935A (en) * | 2025-01-15 | 2025-02-18 | 百吉生物医药(广州)股份有限公司 | A pan-tumor antigen antibody D6 and its application |
CN119462935B (en) * | 2025-01-15 | 2025-03-21 | 百吉生物医药(广州)股份有限公司 | A pan-tumor antigen antibody D6 and its application |
Also Published As
Publication number | Publication date |
---|---|
IL304093A (en) | 2023-08-01 |
US20240010723A1 (en) | 2024-01-11 |
CA3204047A1 (en) | 2022-07-14 |
EP4274615A4 (en) | 2025-01-01 |
CN116887861A (en) | 2023-10-13 |
AU2022205427A1 (en) | 2023-07-13 |
KR20230131478A (en) | 2023-09-13 |
AU2022205427A9 (en) | 2024-02-08 |
JP2024503374A (en) | 2024-01-25 |
EP4274615A1 (en) | 2023-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7559114B2 (en) | CLEC9A BINDING AGENTS AND USES THEREOF | |
US20230295304A1 (en) | Pd-1 and pd-l1 binding agents | |
US20240010723A1 (en) | Antibodies targeted to cd147 | |
US11001631B2 (en) | Clec9A binding agents | |
JP2023112153A (en) | CD8 binding substance | |
CA2887528C (en) | Enhancement of the immune response | |
JPH09507074A (en) | Method for preventing or treating a disease characterized by tumor cells expressing CD40 | |
CN109071679A (en) | The composition and method that cell factor for targeting delivers | |
WO2020238730A1 (en) | Novel cldn18.2 binding molecule | |
US20200354424A1 (en) | Xcr1 binding agents and uses thereof | |
TW202206453A (en) | Virus-specific immune cells expressing chimeric antigen receptors | |
TW202140533A (en) | Combination therapies of chimeric antigen receptors targeting b-cell maturation antigen and gamma secretase inhibitors | |
US20140288279A1 (en) | M-DC8+ Monocyte Depleting Agent for the Prevention or the Treatment of a Condition Associated with a Chronic Hyperactivation of the Immune System | |
CN113621077B (en) | A TIM-3/CD28 fusion protein and CAR-T cells modified by the fusion protein | |
KR20110128923A (en) | Human antibodies against human FAS and uses thereof | |
MX2011007210A (en) | Anti-herpes simplex virus antibodies and methods of use thereof. | |
JP4263391B2 (en) | Use of anti-CX3CR1 antibody, anti-fractalkine antibody and fractalkine | |
WO2018176732A1 (en) | Polypeptide specifically binding to cd56 molecule and use thereof | |
US20250057950A1 (en) | Chimeric antigen receptor targeting gprc5d and application thereof | |
US20240400633A1 (en) | Split human ifn-gamma and tnf-alpha constructs and uses thereof | |
WO2021238910A1 (en) | Anti-coronavirus spike protein antibodies and uses thereof | |
WO2024035343A1 (en) | Chimeric antigen receptor domains | |
WO2024035341A1 (en) | Cd30 antigen-binding molecules | |
WO2023150260A2 (en) | Compounds that target tem8, compositions, and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22737289 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3204047 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023541593 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2022205427 Country of ref document: AU Date of ref document: 20220111 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023013543 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202347051887 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 20237026611 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020237026611 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280014184.X Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022737289 Country of ref document: EP Effective date: 20230811 |
|
ENP | Entry into the national phase |
Ref document number: 112023013543 Country of ref document: BR Kind code of ref document: A2 Effective date: 20230706 |